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Background: Tuberculosis (TB) is a major public health problem in the Horn of Africa, 
Ethiopia having the highest burden which is related to continued transmission of the disease 
to uninfected individuals as a result of delayed diagnosis and treatment. Early detection and 
effective treatment are pre-requisites to bring the high TB load under control. In this regard, 
early health seeking action from patients’ side and prompt diagnosis as well as initiation of 
treatment from health system’s side are essential steps. Currently, efforts are underway to 
identify simple, rapid and accurate diagnostic tests for TB. The aim of this study was to 
evaluate the potential of rESAT-6-CFP-10 and r-crystallin-MPT-83 in the diagnosis of 
pulmonary TB. Besides, we have assessed delay in the diagnosis and treatment of TB patients 
in Northeast Ethiopia. 
Methods: To evaluate the two antigens, 328 pulmonary TB suspects who reported to selected 
health facilities were included consecutively. Sputum and serum samples were collected from 
all participants. Culture, which was used as reference standard, was done on all sputum 
samples. ELISA was run on 204 serum samples using the two antigens. To assess delay, 216 
TB patients who visited DOTS clinics of two health facilities in Afar Region were included 
consecutively from September 2009 to February 2010. Time from onset of symptoms till first 
consultation of formal health providers (patients’ delay) and time from first consultation till 
initiation of treatment (health system’s delay) were analyzed. 
Results: The sensitivity and specificity of rESA-6-CFP-10 antigen were 57.3% and 71.3%, 
respectively whereas the sensitivity and specificity of r-crystallin-MPT-83 antigen were 
20.2% and 92.2%, respectively. The median patients’ and health system’s delay were 20 and 
33.5 days, respectively. The median total delay was 70.5 days with a median treatment delay 
of 1 day. Self-treatment and first visit to non-formal health providers were found to be 
independent predictors of patients’ delay. On the other hand, having extra-pulmonary TB and 
a first visit to health posts/clinics, health centers and private clinics were found to be 
independent predictors of health system’s delay. 
Conclusion: The performance of the two antigens was low and therefore, they can’t be used 
as a substitute or supplementary test in the study area. There is a long delay in the diagnosis 
and initiation of treatment and this was mainly attributable to the health system. Therefore, 
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Interpretation of locally used words 
Health post/ clinic: The lowest health facility in the hierarchy of government health facilities 
staffed with junior nurses and health assistants.  
Health center: The next higher level from health posts/ clinics and it is staffed with nurses of 
different category, health officers, doctors and laboratory technicians. However, the 
professional mix varies from area to area and currently, in remote areas like Afar Region, it is 
hardly possible to find a medical doctor working in a health center.  
Zone       The highest administrative unit next to regions 
Woreda   Each Zone is divided into smaller administrative units called Woreda 
Dagu    A mode of face-to-face communication among the Afar people. It is common among 
the Afars to stop a passerby for Dagu and ask each other information with regard to current 
happenings. It is a cultural responsibility to share information to others promptly.  
Debora    A traditional Afar house made of stick covered with mats. It is easily disassembled 
and transferred from place to place on camel. Two typical Afar houses are depicted on the 
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____________________Chapter 1:  Introduction_____________________ 
1.1. Ethiopia: Country profile 
 1.1.1. Population and demography 
Ethiopia is located in the Horn of Africa sharing borders with Sudan in the west and 
northwest, Kenya in the south, Somalia and Djibouti in the east, and Eritrea in the north and 
northeast. It is one of the ancient countries in the world with an estimated land area of 1.1 
million square kilometres. Ethiopia, the second most populous country in Africa next to 
Nigeria, has an estimated population of 88 million [1]
 
with annual growth rate of 2.6%. The 
majority (84%) of the population live in rural areas [2]. 
  
Administratively, Ethiopia is a Federal Democratic Republic since 1995 with 9 National 
Regional autonomous states. The federal government is responsible for national defence, 
foreign relations and general policy of common interest and benefits [3]. 
 
Ethiopian is one of the countries with the lowest on the Human Poverty Index ranking 92 out 
of 95 countries and about 45% of the population lives below the poverty line [4]. The adult 
literacy rate is estimated to be 36%. Ethiopia’s economy is largely based on agriculture, 
which accounts for 54% of the Gross Domestic Product. Agriculture employs 80% of the 
population and contributes to 90% of the export [5]. 
1.1.2. National health profile 
The country’s health problems mainly emanate from potentially preventable infectious 
diseases and nutritional deficiency states with high mortality and morbidity. However, non-
communicable diseases like diabetes are also emerging as public health problems.  In 2006, 
the life expectancy at birth was 53.4 and 55.4 for males and females, respectively. Infant and 
under-five mortality rates were reported to be 77 and 123 per 1000 live births, respectively 
[6].  
 
Access to basic sanitation and safe water is limited with only 22% and 13% of the population 
having a sustainable access to safe water and basic sanitation, respectively. Nutritional 
deficiency states are also major problems with prevalence of underweight and stunting among 






There is an ongoing effort to expand access to health services. However, the total health 
expenditure is 6 USD per capita per year [4] and the health worker to population ratio is very 
low. For example, the doctors and nurses to population ratios are 1 to 42,706 and 1 to 4,207, 
respectively [6]. 
 
Human Immunodeficiency Virus/ Acquired Immunodeficiency Syndrome (HIV/AIDS), 
malaria and tuberculosis (TB) are major health problems in the country. The national HIV 
prevalence is estimated to be 2.1% although the urban population is disproportionately 
affected [6]. Malaria has resulted in series of epidemics with high morbidity and mortality. 
The annual number of malaria cases reported in 2003 was 8 per 1000 population [4].  
 
Ethiopia carries the highest burden of TB in the Horn of Africa [7] and it stands 7
th
 among 
the 22 high-burden countries in the world. The national notification rate (new and relapse) for 
TB was 151 per 100,000 population [8]. In response to the problem, Directly Observed 
Treatment Short Course (DOTS), the WHO’s center-piece for TB control has been 
introduced in the country in 1994 and has been progressively expanded with decentralization 
of treatment centres. However, with only 60% of the population accessing health services 
within 10 km walk [4], management of TB under the DOTS strategy is a serious challenge 
and hence patients are diagnosed late and Case Detection Rate (CDR) is far below the WHO 
target.  
 
1.2. Literature Review 
1.2.1. Global burden of TB 
TB is among the top 10 causes of death [9] and it is only outranked by HIV/AIDS among 
infectious causes of death worldwide [10]. In low income countries, it is estimated that TB 
accounts for 26 % of avoidable deaths. The majority affected are those between 15 to 59 
years of age, the productive work force [11]. 
In 2006, the global estimated total number of TB cases was 14.4 million, 9.2 million of these 
being new cases. Of the new cases, 4.1 (44%) million were reported to be smear positive 
whereas 8% were HIV co-infected. The mortality related to TB for the same year was 





responsible for recent increase in the global burden of TB and it was estimated that in 2000, 
11% of all TB cases were HIV infected but the range across WHO regions was wide with as 
high as 38% in Africa and as low as 1% in Western Pacific Region [10]. In 2003, the African 
Region which is home only to 11% of the world’s population took the lion’s share of TB-
related burden with 27% of the cases and 31% of the deaths being from this region [12]. In 
2005, TB became declared as an emergency health problem in the WHO African Region 
[13].  
 
Worldwide, 22 countries account for 80% of new TB cases and are labelled as high-burden 
countries [8,10,14]. However, the African Region has the highest estimated incidence rate 
(363 per 100, 000 population compared to 139 per 100,000 population for the world) in the 
world and 12 of the 15 high TB incidence rate countries in the world are from Africa [8]. 
 
The global prevalence of TB started to fall in 1990 and continued till 2006 despite the HIV 
epidemics because HIV in Africa caused a smaller increase in prevalence than incidence or 
death. However, halving prevalence and death rate by 2015 is unlikely because of poor 
progress in African and European Regions where both prevalence and death rates increased 
from 1990 to 2006. The death rate estimate for Africa in 2006 was 83 per 100,000 population 
which is much higher compared to the Region’s target, 21 per 100,000 [8]. 
 
1.2.2. Epidemiology of TB 
TB is an infectious disease caused by M. tuberculosis complex. It is primarily transmitted 
from man to man through inhalation of suspended infectious droplets in the air containing 
live bacilli. However, transmission can occur from animals to humans or vice versa [15]. 
    
It is estimated that a third of the world population is infected with Mycobacterium 
tuberculosis. In high income countries, more than 80% of infected individuals are above 50 
years of age as opposed to the situation in low income countries where 75% of infected 
individuals are below 50 years of age and this is a reflection of differences in population 
structure and transmission levels [11].  
 
Smear positive pulmonary TB patients are the most important source of infection compared 





pulmonary TB cases do as well have significant contribution to transmission with a relative 
transmission of 22% compared to smear positives [17]. 
 
Although the prevalence of infection is high, only a small fraction of those infected develop 
the disease. It is not clear why some do and some do not progress to disease after infection. 
Among the different factors identified as important risks for the development of TB include a 
recent infection (< 1 year) with the bacilli, HIV/AIDS, immunosuppressive drugs, 
underweight, diabetes, smoking, malnutrition, alcoholism, crowded living conditions, indoor 
air pollution and genetic factors with inherited susceptibility and being male [16,18].  
 
Epidemiological data has consistently shown that TB is primarily a disease of men. Although 
differences in accessing health services may contribute to the differences among men and 
women, it seems that there is a real epidemiologic difference in terms of risk of exposure and 
susceptibility for developing disease [14]. In terms of Disability Adjusted Life Years lost, the 
overall burden of TB is 23% higher in males than females except among HIV co-infected 
patients where the reverse is true. Moreover, the prevalence of TB is estimated to be 2.6 
times higher among the poor than among the non-poor [9]. 
 
Depending on the organs involved, patients are grouped as having pulmonary TB or extra-
pulmonary TB. Pulmonary TB primarily affecting the lungs accounts for 80-85% in HIV 
negative TB patients whereas extra-pulmonary TB which involves organs other than the 
lungs accounts for 15-20% of TB cases. However, in HIV infected patients, the proportion of 
extra-pulmonary TB may reach as high as 50% [19].  
 
Although any organ can be involved, lymph nodes are the primary site of extra-pulmonary 
TB accounting for 35-50% of the cases. It is relatively common in children, young adults and 
females. Single lymph node involvement occurs in 70% of the cases in HIV negative 
patients; on the other hand, multiple lymph node involvement in HIV positive patients 
reaches up to 90% [19]. 
 
The main isolate from TB patients is M. tuberculosis. Another important species that 
contributes to TB prevalence is M.bovis.  The prevalence of M.bovis among TB patients is 
not well established in Africa; however, there is evidence that it significantly contributes to 





article [20]. In a study carried out in pastoral areas of Tanzania, 28.6% of the isolates from 
TB lymphadenitis patients were M.bovis [21]. 
 
In Ethiopia, the prevalence of bovine TB among humans is not well established. A review on 
bovine TB in animals and humans indicated a prevalence of 16.3% and 29.2% among human 
patients based on two reports [22]. Raw milk consumption is a common practice in the 
country. In a study addressing epidemiology of bovine TB in cattle and farmers’ awareness, it 
was found out that nearly 50% of adults drank raw milk regularly and more than 60% of 
respondents did not regularly boil milk for their babies. Moreover, their knowledge on bovine 
TB was found to be poor [23]. With the background of large livestock, high HIV prevalence 
and a common practice of drinking raw milk in rural areas, the risk of spillover of zoonotic 
bovine TB to rural communities is expected to be high in the country [22]. 
 
1.2.3. Immunopathogenesis of TB 
Efforts to understand the pathogenesis of TB started long before its aetiology was described 
and late in the 19
th
 century, Robert Koch made a tremendous contribution in this regard. He 
identified M.tuberculosis, developed staining and culture techniques, described mode of 
transmission, prepared tuberculin [24] and attempted to develop a therapy [25]. Subsequently, 
advances have been made in the immunology, pathogenesis and molecular biology of 
M.tuberculosis.  
 
The tubercle bacilli primarily enter via the respiratory route as respiratory droplet nuclei. 
Subsequently, droplets get deposited on the alveolar space and bacilli are taken up by 
macrophages. Infected macrophages either remain in the lungs or get disseminated to other 
organs of the body with subsequent risk of extra-pulmonary TB. Moreover, M.bovis is 
primarily a zoonotic infection transmitted from animals to humans and manifest as extra-
pulmonary TB. 
 
Cell mediated immunity plays a major role in controlling infection. Once the bacilli are 
engulfed, activated alveolar macrophages are able to transfer the phagosome-endosome cargo 
containing the bacilli into lysosome where the pathogen is effectively destroyed. However, 






Phagocytosis of the pathogen is accompanied by an inflammatory immune response with 
accumulation of different immune cells and subsequent formation of granuloma. The 
granuloma characteristically contains a small number of infected phagocytes surrounded by 
activated monocytes /macrophages which in turn is surrounded by activated lymphocytes 
[25]. 
 
 If the immune response is able to contain the infection, the granuloma shrinks. However, 
failure to contain the infection results an increase in size and cellularity of the granuloma 
with necrosis at its centre. A granuloma close to the surface of a bronchus may rupture as a 
result of tissue destruction and a breach on mucosal surface. This results in the classic 
symptoms of TB, a persistent cough associated with bloody sputum and it is commonly 
referred to as cavitory TB. Patients with such type of lesion are highly infectious [25]. 
  
Tissue destruction in TB is immunopathological in nature resulting from the effects of both 
the pathogen and the host immune response. The host immune response involves an array of 
immune cells and inflammatory cytokines interacting with different mycobacterial antigens 
and the balance between these is believed to be reflected by the granuloma formation [25].  
 
Generally, infection is asymptomatic (latent TB) and the lifetime risk of TB after infection is 
about 10% [16]. The presence of asymptomatic TB infection poses a challenge to 
differentiate between active and latent TB using immune-based tests. 
 
1.2.4. Management of TB 
Management of TB patients involves early (& accurate) diagnosis, and appropriate treatment 
to reduce transmission, morbidity, mortality and development of drug resistance. The entry 
point to this effort is suspecting TB in patients with suggestive symptoms. Clinically, patients 
with pulmonary TB mainly present with productive cough, haemoptysis, shortness of 
breathing, chest pain and other constitutional symptoms. On the other hand, clinical 
presentation of patients with extra-pulmonary TB depends on the organs involved [27]. 
 
Currently, detection of patients with TB requires that patients are aware of their symptoms 
and have access to health facilities. Once they come in contact with a health facility, the 





in turn depends on the type of test available and the skills of the laboratory personnel. In this 
complex continuum, anything could go wrong and patients may remain undetected leading to 
high morbidity and mortality as well as continued transmission. 
 
To improve case detection as well as treatment success, WHO launched DOTS in the early 
1990s. One of the five key elements of DOTS is diagnosis of TB using smear microscopy 
which suffers from low sensitivity. Under the DOTS programme, WHO aimed to detect 70% 
of the smear positive cases and treat 85% of them successfully by 2005. However, CDR 
remained low standing at 61% in 2006. In fact, the case detection rate has begun falling in 
China and India whereas in Africa, it remained far below the target currently estimated to be 
only 46%. Even worse, the CDR in Ethiopia is just 27%, the lowest next to Nigeria among 
high-burden countries [8]. However, the concept of CDR is debated and it seems difficult to 
assess the performance of countries towards detecting smear positive pulmonary TB patients.  
 
CDR is the proportion of incident smear-positive TB cases detected through a TB program. 
The denominator of CDR, incidence rate, has been estimated based on annual risk for TB 
infection. It has been estimated that a 1% annual risk of infection without control measures 
would correspond with an incidence for new cases of smear-positive TB of approximately 50 
per 100,000. The annual risk of infection, on the other hand, is measured through tuberculin 
surveys. Tuberculin survey has a major draw-back: cross-reaction with BCG and 
environmental mycobacteria. Moreover, the relationship between risk of infection and 
incidence rate is affected by HIV infection and the quality of control measures. Because of 
the above problems, the validity of CDR as an indicator is being debated and alternative 
indicators are suggested. One such indicator suggested is patient diagnostic rate which is 
defined as the number of newly reported cases of smear-positive TB per 100,000 population 
per year divided by the prevalence of new cases of smear-positive TB per 100,000 population 
[28]. However, this requires countries to undertake prevalence surveys every 5 to 10 years.   
 
Another study proposes the use of treatment delay (time interval between onset of symptoms 
and initiation of treatment) to monitor infectious pool. According to this study, a systematic 
recording of treatment delay in TB treatment clinics could help in estimating the infectious 






The low CDR is in sharp contrast to treatment success which is very close to the set target at 
global as well as regional level. Although successful treatment of cases is important to 
prevent drug resistance, the ultimate control of TB depends on a balanced effort in detecting 
as well as treating TB patients or else diagnostic delay with late detection will lead to 
perpetuation of the epidemic especially in high burden countries where the laboratory 
diagnosis is poor [30].  
 
Diagnostic delay is defined as patients’ delay in seeking health care, health providers’ delay 
in making prompt and accurate diagnosis with subsequent initiation of treatment or both. In 
some studies, the acceptable period from onset of symptoms till reporting to a health facility 
was taken as 30 days [31-33]. Another study in Australia used 30 days as a cut-off for delay 
from onset of symptoms till initiation of treatment based on a suggestion from a panel of 
experts. Similarly, the acceptable period from determination of sputum positivity to initiation 
of treatment was taken as 3 days [34]. On the other hand, others take the median value of 
observed data as a cut-off point [35-37]. 
 
According to a review on diagnostic delay, the majority of the studies reported a total delay 
ranging from 60 to 90 days. The contribution of patients and health systems to the total delay 
is not consistent across many studies; in some studies, the major portion of total delay was 
attributable to patients whereas in others health systems take the major share. Although a 
number of risk factors for delay were reported, there was no consistency among the different 
studies. Some of the risk factors reported include initial visit to traditional or unqualified 
practitioners, initial visit to private practitioners, old age, female sex, poverty, and low 
educational level [38]. 
 
 A vicious circle of repeated visits at the same level has been especially found to be an 
important reason for longer delay and three groups of health care providers were particularly 
found to be linked to the vicious cycle: low level government health facilities, private 
practitioners and unqualified practitioners [38]. Apart from low awareness, lack of simple and 






1.2.5. Diagnostics for TB 
Currently, the diagnosis of TB is largely based on a combination of clinical criteria and 
conventional laboratory diagnostics (smear microscopy, culture, tuberculin skin test and 
radiology). Of these, sputum microscopy is the routinely available and most important test in 
low and middle income countries. However, all the existing conventional diagnostic tests 
have serious limitations and diagnostic delay is a major problem. In a review on diagnostic 
delay, it was found that smear negative pulmonary TB, extra-pulmonary TB and HIV co-
infected TB patients suffer from significant diagnostic delay [38].  
 
In low income countries, diagnosis of smear negative pulmonary TB and extra-pulmonary TB 
rests on either clinical criteria alone or in combination with radiological findings because of 
the absence of other alternative diagnostic tools. However, the clinical presentation of TB is 
non-specific mimicking many diseases and hence it is not reliable for diagnosis. In addition 
to the conventional diagnostic tests, molecular and immune-based tests have been used in the 
diagnosis of TB. A brief description of the major diagnostic tests for pulmonary TB follows. 
 
1.2.5.1. Radiology 
The radiological findings in pulmonary TB are well described and it has a high sensitivity. 
However, in HIV infected TB patients, the radiological findings are variable with atypical 
findings and hence demanding experienced radiologists. Even then low specificity of this 
method remains a concern. In a study done in Kenya, the investigators found that radiology 
has a sensitivity of 92 % and a specificity of 63% [39]. Moreover, for low income countries, 
availability of equipment and running cost issues remain central problems. 
 
1.2.5.2. Bacteriologic methods 
Smear microscopy and culture are used as techniques of identifying bacilli from specimens. 
Smear microscopy on unprocessed sputum remains the standard diagnostic method for 
pulmonary TB in low and middle income countries where 90% of TB is found [40]. It is 
positive for those patients having 5,000 to 10,000 bacilli per millilitre of specimen [41]. 
Although its specificity is about 98%, the sensitivity is variable ranging from 20-80 % in 
pulmonary TB [17,41,42]; high in patients with advanced and cavitory TB whereas low in 





it needs two visits and technically burdensome requiring a good microscope as well as a 
trained expert [30] with external quality control in place.  
 
Culture overcomes the low sensitivity of sputum microscopy. M. tuberculosis can be detected 
using culture at a concentration of 10 to 100 organisms per ml of specimen and hence the 
sensitivity ranges from 80-93% with a specificity of 98%. The major limitation of culture is 
the time it takes to yield results. Although liquid media seem to shorten the duration to yield 
results in 2 weeks time [41], it is still unacceptably long and hence is not important for quick 
clinical decision. Moreover, it requires a quality and dedicated laboratory with trained 
expertise making it expensive to run it [40] and hence few primary diagnostic laboratories in 
low income countries have culture facilities [17]. 
  
1.2.5.3. Molecular methods 
Better diagnostic tests are being developed as a result of advances in molecular techniques. 
Polymerase chain reaction-based molecular tests are already in the market; Amplicor MTB 
test (Roche diagnostics System) and Amplifier Mycobacterial Tuberculosis Direct test are 
approved by Food and Drug Administration. The sensitivity of these tests is dependent on 
smear status of samples: in a review paper including those studies which used culture as a 
standard, among smear positives pooled sensitivity and specificity were 96% and 85%, 
respectively whereas in smear negative patients, pooled sensitivity and specificity were found 
to be 66% and 98%, respectively [43] making it less beneficial for smear negative patients. 
Moreover, they have low specificity under field conditions [44]. 
 
Besides, these tests are expensive and require sophisticated laboratories with trained expertise 
making them inaccessible for low and middle income countries. In a case study to assess the 
cost effectiveness of molecular tests, it was reported that they are not cost effective at the 
moment [45]. Moreover, the fact that these tests require specimens from affected areas makes 
them less appealing for patients with extra-pulmonary TB. 
 
1.2.5.4. Immune-based tests 
Immunological tests are meant to detect immune response (cellular or humoral) or antigens in 





areas. Currently, cellular immune response is measured using tuberculin skin test (TST) and 
interferon gamma release assay (IGRA).  
 
TST involves intradermal injection of TB antigens and subsequent measurement of the size 
of induration. It has been used for epidemiologic surveys and in some cases for diagnostic 
purpose; in high income countries, it is used to diagnose latent TB. It has low specificity and 
cannot differentiate active from latent TB, Bacillus Calmette Guerin (BCG) vaccination as 
well as infection with environmental mycobacteria. Therefore, in areas where TB is endemic, 
BCG vaccination is a routine practice or infection with environmental mycobacteria is 
common, its role in the diagnosis of TB is limited [17].  Moreover, TST tends to be negative 
in patients with clinical TB [46] and HIV infected patients [47]. 
 
IGRA assesses the cellular immune response to specific TB antigens through measurement of 
interferon gamma (IFN-) produced by T-cells. Currently, there are two commercially 
available tests:  QuantiFERON-TB Gold and T-SPOT.TB tests. These tests have a sensitivity 
ranging from 80 to 95% and are highly specific (90-100%) for TB infection. Moreover, they 
are unaffected by BCG vaccination status. Therefore, they are promising tools for screening 
TB infection with several advantages over TST like one patient visit, higher specificity and 
are ex vivo tests. However, they have low specificity for active TB [41]. In endemic countries 
where latent TB infection is prevalent, a good immune-based test should differentiate active 
TB from latent infection. 
 
 As a result of the limitations of the existing tests, diagnosis of TB poses a formidable 
challenge with a consequence of health system’s delay. Therefore, simple, accurate, 
affordable and point of care diagnostic tools are in urgent need either to replace or 
supplement the existing tools especially in resource constrained areas. Immune-based tests 
based on antibody detection have the potential to fulfil these demands.  
 
Although the role of humoral immunity in TB infection is not well established, exposure to 
M.tuberculosis antigens results in the production of antibodies which could be used for 
diagnosis. In this regard, the first attempt was made in 1898 by Arloing as a technique of 
haemagglutination. However, the sensitivity and specificity remained unacceptable and the 





first time and since then evaluation of different potential antigens was carried out extensively 
[48]. Evaluation of serological tests before 1990 was done on crude antigens and hence 
specificity was low because of cross-reaction with other antigens. After 1990, purified and 
recombinant antigens were introduced with subsequent improvements in the specificity of the 
tests [48,49].  
 
To this end, a number of potential antigens have been identified and evaluated for their 
diagnostic potential for TB using serum samples. A review of studies on serological tests for 
TB described the different potential antigens identified and evaluated. Among these antigens, 
the 38kDa and A60 have been extensively evaluated either in combination with other 
antigens or alone [48]; the tests are either in ELISA or rapid formats such as 
immunochromatographic tests and primarily detect IgG, IgA and IgM.  Currently dozens of 
such tests are commercialized in rapid formats and used in low and middle income countries 
with estimated annual sales volume of 3,000 to 300,000 [44]. Moreover, it is estimated that 
more than 40 types of rapid serologic tests have already entered in the market [40] and mostly 
also left.   
 
A review of studies done on commercial tests for the diagnosis of pulmonary TB [49] and 
extra-pulmonary TB [50] showed variation in accuracy of tests across studies with 
sensitivities ranging from 0% to 100% and specificities ranging from 47% to 100%. This 
variation was attributed to differences in the antigen used, antibody detected, setting, stage of 
disease, study design, and status of specimen (fresh or archived). Moreover, the type of TB 
has an influence on the performance of these tests. Sensitivity is low in smear negative 
pulmonary TB [51, 52], extra-pulmonary TB [51-54], and HIV co-infected patients compared 
to HIV negative smear positive pulmonary TB [54]. Moreover, a recent head to head 
evaluation of 19 commercial rapid tests using culture as a reference in pulmonary TB patients 
revealed a low sensitivity (0.97% to 59.7%) and a variable specificity (53% to 98.7%). 
Generally, those tests with high sensitivity have low specificity and vice versa [40]. 
 
There are a number of antigens evaluated in-house and not yet commercialized; some of these 
antigens are reported to be promising. Moreover, protein antigens achieved high specificity; 
combined antigens have better performance compared to single antigens, and potential 






ESAT-6 (6 kDa Early Secretory Antigen Target) and CFP-10 (10 kDa Culture Filtrate 
Protein) are among several immunogenic, early secreted, culture filtrate proteins obtained 
from M.tuberculosis complex. They are encoded within Region of Difference 1 (RD1) which 
is absent from BCG strains and other environmental mycobacteria [56]. They have been used 
for cell mediated-based tests. These antigens have been evaluated extensively in the diagnosis 
of latent TB. Recently, the potential of these two antigens for the diagnosis of active TB has 
been evaluated by a few studies. A study in Denmark has evaluated the performance of these 
antigens using whole blood to measure cytokine level (IFN-) and found a sensitivity of 85% 
and specificity of 60% [57]. 
 
On the other hand, a few studies were carried out to evaluate the humoral immune response 
and serodiagnostic efficacy of ESAT-6 and CFP-10 antigens in addition to other antigens. 
One of these studies was done in Poland and reported a sensitivity of 64.9% and specificity of 
89.9% for rESAT-6 and sensitivity of 66% and specificity of 85.2% for rCFP-10 [58]. 
Another study done in China where investigators used rESAT-6-CFP-10 as a fusion antigen 
reported a sensitivity and specificity of 73.2% and 73.8%, respectively [59]. However, these 
studies used healthy controls and this might have lead to a higher specificity than would be 
expected from clinically suspected non-TB patients [49]. 
 
The other antigens reported to be immuno-dominant are MPT-83 and -crystallin.  MPT-83 
is an immunologically active cell wall associated protein [60] found in M.tuberculosis. -
crystallin is a 16 kDa regulatory cell wall protein. It is a predominant stationary phase protein 
and it is said to be essential for the long term survival of M.tuberculosis [48,61]. MPT-83 
combined with other antigens has been shown to confer protection against pulmonary TB in a 
mouse model [62].  
 
The performance of -crystallin and MPT-83 antigens was assessed separately for the 
diagnosis of pulmonary TB by some studies. A study from United States reported a 
sensitivity and specificity for r16 kDa as 17% and 95%, respectively whereas the sensitivity 
and specificity of rMPT-83 in the same study were 9% and 84%, respectively [63]. Similarly, 
another study from United States reported the sensitivity and specificity of r16 kDa antigen 
for the IgG isotope as 62% and 100%, respectively [64]. A recent study in Guinea comparing 





showed that there is no difference between the two groups with regard to their immune 
response to rMPT-83 antigen [65].  
  
Although a number of potential antigens are evaluated, the performance of these tests varied 
significantly. Variation from population to population for the same antigen has been reported 
[66]. This variation might be due to differences in the genetics of the population studied, HIV 
prevalence, stage of disease, the prevalence of non-mycobacterium infections, variation in the 
antigens of different strains, the degree of repeated infections, the prevalence of nutritional 
deficiencies as well as prevalence of parasitic infections. This implies that serologic tests for 
TB should be evaluated at different settings with different population subgroups and different 
levels of TB infection.  
 
Many of the studies done had methodological weaknesses. Some of the weaknesses include 
“inappropriate composition of study groups; failure to analyse test performance in pertinent 
subgroups and bias in the selection of patients`` [67]. Many of the studies are limited to in-
house evaluation of the tests or field evaluation at tertiary level excluding primary health care 
levels. Moreover, only a few studies assessed the accuracy of these tests in Africa [68-70] 
where such tests could have been more important than anywhere else.  
 
Evaluating a combination of different antigens at different settings with improved 
methodology is essential to accurately assess the performance of such antigens. Therefore, we 
evaluated the sero-diagnostic potential of two fusion recombinant antigens: rCFP-10-ESAT-6 
and rα-crystallin-MPT-83 (hereafter called serology study) in the diagnosis of active 
pulmonary TB in an endemic setting. Moreover, we assessed delay in the diagnosis and 
treatment of TB patients (hereafter called delay study) in two health facilities in Afar Region 
where such a study has never been reported. 
 
1.3. Research Question, Hypothesis and Objectives 
 Research Questions 
1. Could ELISA using rESAT-6/CFP-10 and rα-crystallin-MPT-83 antigens have better 
performance than smear microscopy in identifying active TB cases in health facilities of the 





2. What is the duration of patients’, health system’s and total delay among TB patients in the 
study area?  
3. What are the predictors of delay in the diagnosis and treatment of TB patients in the study 
area? 
Hypothesis 
1. rESAT-6-CFP-10 and rα-crystallin-MPT-83 antigens have better performance in the 
diagnosis of active pulmonary TB than smear microscopy in selected health facilities in the 
study area. 
2. There is a long patients’ as well as health system’s delay in the diagnosis and treatment of 
TB patients and socio-demographic & health service related factors are the major predictors 
of delay.   
 
General objective: 
 To assess diagnostic delay among TB patients and evaluate the potential of two recombinant 
fusion antigens in the diagnosis of active pulmonary TB in North-eastern Ethiopia. 
Specific objectives: 
1. To determine the sensitivity, specificity and likelihood ratios of rESAT-6/CFP-10 
and rα-crystallin-MPT-83 antigens among pulmonary TB suspects in the study area, 
taking culture as a reference test 
2. To measure the length of delay in the diagnosis and treatment of TB  











_____________________Chapter 2: Methodology_____________________ 
2.1. Study area 
The study was conducted primarily in the Afar Regional State, northeast Ethiopia. Moreover, 
since the Afar people frequently visit health institutions in Dessie, two private hospitals and a 
clinic located in Dessie were included in the study. Dessie Town, with a population of 
120,000, is located 400 km Northeast of Addis Ababa in Amhara Regional State. Four 
hospitals (3 of which are privately-owned) and a number of privately owned clinics are found 
in the town and with its attractive climate, it remains the most frequently visited town by the 
Afar people outside of Afar Region.  
 
The Afar Region is one of the 9 administrative regions of Ethiopia with estimated area of 
100,000 square km [3]. Semera, capital of the Region, is about 600 km northeast of Addis 
Ababa on the main road to Djibouti. The Region shares boundary with four national regional 
states (Tigray in the northwest, Amhara in the southwest, Oromia in the south and Somalia in 
the southeast) and two international boundaries (Djibouti in the east and Eritrea in the 
northeast) [71]. 
 
Administratively, the Region is divided into 5 zones and 30 districts (“Woredas”). In 2007, 
the population size of the Region was about 1.4 million with annual growth rate of 2.2%. 
About 87% of the population were in the rural areas of the Region and the male to female 
ratio was 1.23 [2]. The Region is mainly lowland with 87% of the land being below 900m 
above sea level; it is mainly arid and semiarid with annual mean temperature above 27°c and 
annual mean rainfall between 500-100mm [71]. 
 
The livelihood of the Afar people is based on livestock production with limited crop 
production. Animals are used as a source of food, income and transport. In 2006, it was 
estimated that there were 10,000,000 livestock in the Region, of which 41.93% were goats 
and the rest included sheep, cattle and camel. Seasonal migration in search of water and 
pasture for their animals is a major coping strategy during the dry season [71].  
 
Infrastructure development is poor with limited access to telecommunication, electricity, 
postal and road services. Moreover, only 28% of the population has potable water supply 





during the present study), 42 health centers, 45 health stations, 154 health posts and 6 private 
clinics. There were 10 medical doctors, 16 health officers, 208 nurses, 7 laboratory 
technicians, and 12 pharmacy technicians [6]. The health service coverage was 40% in 2005 
[71]. The infant and under-five mortality rates in the Region were reported to be 61 and 123 
per 1000 live births, respectively. HIV prevalence in the region was 1.9% [6].  
 
Although the prevalence of TB in the Region is not known, it is an endemic area with a 
notification rate of 103 per 100,000 populations in 2006 [6]. Their life style like their 
intimacy with their cattle, their dependency for their food on animal products especially raw 
milk, and the repeated stress related to migration they face is expected to put them at a greater 
risk for TB with high transmission. The population constantly moves from place to place in 
search of pasture and water for their cattle and this compromises health service utilization. 
Moreover, the health service coverage is low with the majority of health facilities found on 
the main roads. Early and rapid diagnosis at the lowest health facility level would have a 
tremendous impact on TB control programmes in such areas. 
 
2.2. Study design 
A quantitative, facility based cross-sectional study was employed to achieve the 
aforementioned objectives. For the serology study, pulmonary TB suspected patients visiting 
selected health facilities were recruited in a consecutive series and examined at one point in 
time and sample was collected. Thus, all samples from pulmonary TB suspects were tested 
for TB using the reference standard (culture) and smear microscopy (done at the respective 
health facilities). Furthermore, 5 ml blood was withdrawn from these individuals for running 
ELISA using rESAT-6-CFP-10 and rα-crystallin-MPT-83 antigens. ELISA was run at Aklilu 
Lemma Institute of Pathobiology (ALIPB), Addis Ababa University laboratory. Since 
suspects were recruited consecutively with no differential selection of cases and controls, 
comparability of study participants was ensured. In this way, the selected study design 
overcomes the limitations of diagnostic case-control study design [72]. 
 
For delay study, because of poor infrastructure and security threats in the Region, we selected 
Dubti hospital and Asayta health center, both located in Zone one where nearly a third of the 
Region’s population lives [2]. We included all newly diagnosed TB patients coming to these 





2.3. Study population 
TB management in Ethiopia is currently based on passive case detection in which patients 
consult health care providers by their own initiative. Subsequently, TB suspects are managed 
or referred to the next higher level depending on the presence of TB management services. 
Therefore, the study population for the serology study was all pulmonary TB suspects who 
came to the following health facilities: Dubti Hospital and Awash Health Center in Afar 
Region and Selam Hospital, Bati Hospital and Amir Higher Clinic in Dessie Town.  
Similarly, for the delay study, TB patients just diagnosed and came to the DOTS clinics of 
the two health facilities were included consecutively in the study period.   
 
2.4. Inclusion and exclusion criteria 
Study participants were selected from the study population according to the following 
inclusion and exclusion criteria.  
Inclusion criteria: 
Patients fulfilling all of the following were included in the study: 
 Patients suspected of having pulmonary TB as judged by the respective health 
workers in selected health institutions (for serology study). 
 Patients just diagnosed as new TB cases and sent for treatment to the DOTS clinic 
(for delay study) 
 Age  >18 years  
 Volunteered to participate in the study  
Exclusion criteria: 
Patients with either of the following were excluded 
 Critically ill patients requiring urgent intervention 
 Patients with proven coagulation problems (for serology study) 








2.5. Sampling method and sample size 
For the serology study, all participants fulfilling the inclusion criteria were recruited until the 
desired sample size was attained.  
Taking a sensitivity of 73% from a previous study (59) with a 95% confidence interval of 
10%, using the following formula [73]            
                                                                        n >  (1.96)
2
[ p (1-p)],  
                                                                                        (CI)
 2
                               
 where p is the sensitivity, n is sample size for the cases and CI is the confidence interval, 
approximately 76 true cases were needed as determined by the reference test. At the 
beginning, assuming a 15% prevalence of culture positive pulmonary TB among pulmonary 
TB suspects, the calculated  sample size for the suspects to be included in our study was 507. 
However, we were able to identify 101 culture positives from 328 pulmonary TB suspects 
and therefore, sample collection was concluded.  
 
For the assessment of delay, we recruited newly diagnosed TB patients from two DOTS 
clinics in a consecutive manner over the study period. They were interviewed with structured 
questionnaire. 
 
2.6. Reference standard for the serology study 
The best diagnostic test available for TB is culture and therefore it was used as a reference 
standard in all patients suspected of pulmonary TB. Smear microscopy on all sputum samples 
was done at health facilities and this allowed us to determine the sensitivity of the antigens 
among those who were smear negative but culture positive pulmonary TB cases.  
 
2.7. Sample collection, transport, storage and processing 
Our project site was far from the laboratory center for culture and serology. Therefore, 
appropriate collection, storage and transport of samples were essential steps to ensure the 
reliability of the results.  Serum samples were kept at -20 °C and sputum samples were stored 
at 4 °C at study sites until transported to ALIPB laboratory within 5-10 days. Sputum and 
serum were transported to ALIPB laboratory under the necessary precautions to maintain the 
quality of samples. Subsequently, serum samples were kept at -20 °C until ELISA was run. 





2.7.1. Sputum collection, transport and storage 
Sterile sputum cups, approximately 10ml, were used for sputum collection. Participants 
suspected of pulmonary TB were given sputum cups after explaining how to produce a 
quality (mucoid or mucopurulent) and adequate (3-5 ml) sputum [74]. Sputum cups were 
labelled properly with a unique identification number which corresponds to every study 
participant. 
 
It is a routine practice to collect 3 sputum samples for the diagnosis of pulmonary TB. A leak 




Laboratory technicians/technologists working in selected health facilities were responsible 
for collecting serum samples. About 5 ml of blood was drawn by venipuncture under aseptic 
technique (70% alcohol was used to clean the overlying skin and a sterile needle and syringe 
was used to draw blood) from participants. After allowing the blood to clot for 10-30 
minutes, it was centrifuged and serum was separated, divided into two aliquots in cryotubes 
and stored as described above.  
 
2.7.3. Smear microscopy 
Smear preparation, staining and examination was done according to WHO guideline [75].  
Briefly, new, clean, unscratched slides were labelled with the corresponding patient identity 
number and specimen were transferred, spread and allowed to air dry for 15 minutes. Then 
fixing was made by passing the slides through a flame 3 times. The slides were flooded with 
Ziehl- Neelsen carbolfuchsin. Gentle heating for 3 to 5 minutes was done to facilitate 
staining. After rinsing the slides with clean water, slides were flooded with 25% sulphuric 
acid for 3 minutes as a decolourizing agent. Subsequently, slides were rinsed with clean water 
and methyl blue was used as a counter stain for 1 minute. The slides were then air dried. 
Using 100x oil immersion objective, smears were examined by laboratory technicians at the 






2.7.4. Bacterial culture 
Specimen were processed and cultured according to WHO guideline [74]. Briefly, sputum 
sample were homogenised and decontaminated using Petroff method. One unit volume of 
sputum was mixed with equal volume of 4% 
1
NaOH and shaken. After letting stand for 15 
minutes at room temperature with occasional shaking, it was centrifuged at 3,000 rpm for 15 
minutes. The supernatant was poured off while the sediment was neutralized with 0.1N 
2
HCL 
using phenol red as an indicator. Neutralization was achieved when the colour of the solution 
was changed from purple to yellow. After removing the condensed moisture in the slant of 
culture media, 0.2-0.4ml (2-4 drops or 2-4 loopfuls) of the centrifuged sediment was 
inoculated and distributed over the slant surface. Four slopes of Lowenstein-Jensen media 
were inoculated per specimen, two of them containing pyruvate to isolate M.bovis. Culture 
media were kept in slant position for the first 24 hrs and then upright position at 37°c.  
 
Subsequently, inspection of media was done 72 hrs after inoculation to see the fluid content 
and then after one week to see for the growth of rapidly growing mycobacteria to 
differentiate them from M.tuberculosis. Subsequent inspection of media after 3-4 weeks was 
done to look for growth of M.tuberculosis or other slow growing contaminants. Those 
without growth after 8 weeks were discarded and reported as negatives. Liquefied or 
completely contaminated media were discarded. Partially contaminated media were kept until 
growth of M.tuberculosis is seen or until the 8
th
 week. In late contamination, Acid Fast 
Bacilli (AFB) staining was done to see for growth of M.tuberculosis.  
 
2.7.5. ELISA 
Antigens were donated by Statens Serum Institut, Denmark and optimization was done at 
Norwegian Institute of Public Health. Nunc Maxisorb ELISA plates (flat bottom, Nunc 
Maxisorp, Roskilde, Denmark) were coated with rESAT-6-CFP10 and rα-crystallin-MPT-83 
antigen at 4 μg/ml (0.4 μg antigen per well) in fresh 10 mM 3PBS (pH 7.4). The plates were 
then incubated for two days at 4 °C before use. After washing 5 times with PBS containing 
                                                          
1 NaOH= sodium hydroxide 
2 HCL= Hydrochloric acid 





0.05% Tween20™, 100 μl of PBS containing 2% 4BSA was added to each well as a blocking 
solution and then incubated at 37°C for 1 hour. After washing as described above, 100 μl of 
patient serum diluted at 1:75 in PBS containing Tween20™ 0.05% and 2% BSA was added 
in each well and plates were incubated at 37 °C for 1 hour. Plates were washed as above and 
100 μl of sigma product A3187 anti-human IgG-alkaline phosphatase diluted at 1:5000 in 
PBS containing Tween20™ 0.05% and 2% BSA was added in each well. The plates were 
incubated at 37°C for 1 hour. ELISA was developed using sigma product S0942 alkaline 
phosphatase-substrate dissolved in 10% dietanolamine buffer (pH=9.8). Two tablets of sigma 
product S0942 were dissolved per 10 ml dietanolamine buffer and 100 μl of this solution was 
added per well. Signals were recorded at 405 nm, at 30 minutes. Samples were run as 
duplicates and mean value of the two Optical Density (OD) readings were taken for analysis.   
 
Positive and negative control serums were used in every plate. The negative control serum 
was from an apparently healthy individual who had no chest x-ray abnormality. Besides, the 
patient was TST and interferon gamma negative. On the other hand, the positive control 
serum was from culture confirmed pulmonary TB patient with high OD values for both 
antigens. 
 
2.7.6. HIV test 
HIV testing was performed since the performance of the test might be affected by the HIV 
status of participants. It was done according to the existing national algorithm used to 
diagnose HIV. The algorithm utilizes three rapid HIV test kits: KHB test (Shanghi Kehua 
Bio-engineering, Ltd, China), HIV1/2 STAT-PAK® ASSAY (CHEMBIO Diagnostic 
systems, Inc, USA) and Uni-Gold TM (Trinity Biotech, USA). KHB was used as a screening 
test whereas STAT-PAK was required to confirm the initial HIV diagnosis made with KHB. 
Uni-Gold was utilized as a tie-breaker when the screening and confirmatory test results are 
discordant. Those patients with HIV infection were counselled and referred to antiretroviral 
therapy clinics for further intervention. 
                                                          






2.8. Management of patients with TB 
The management of patients with TB in Ethiopia is based on the national guidelines. Smear 
microscopy is the standard diagnostic procedure for pulmonary TB. Generally, smear positive 
pulmonary TB is confirmed when a patient has 2 AFB smear positive results or one AFB 
smear positive result with radiological abnormalities consistent with pulmonary TB (76).  For 
smear negative patients, chest X-ray (if available) and clinical findings were used to establish 
diagnosis. Culture is not routinely used for diagnostic purposes. Patients with TB are treated 
under the DOTS programme adopted from WHO guideline. The management of patients who 
participated in our study was based on the existing national guidelines. Local health workers 
were responsible for patient management as usual and patients were not delayed until our 
results were ready. However, we provided culture results to the respective health institutions 
for further patient management decisions. Serology result was not used in making decision in 
patient management. 
 
2.9. Operational definitions of terms and variables 
Dependent variables: 
Pulmonary TB suspects: pulmonary TB suspects were defined according to the national 
guidelines: patients having cough for 3 weeks or more are pulmonary TB suspects 
Presence or absence of disease (final diagnosis): true cases or non-cases as determined by 
culture and smear microscopy 
Test result: positive or negative result as determined by rESAT-6/CFP-10 and rα-crystallin-
MPT-83 recombinant fusion antigens 
Patients’ delay: The time interval between onset of symptoms of TB and first presentation to 
a professional health provider. 
Health system’s delay: The time interval between date of first presentation of patients to a 
professional health provider and initiation of treatment. 
Treatment delay: The time interval between date of diagnosis and initiation of treatment 
Total delay: The time interval between onset of symptoms of TB and initiation of treatment. 
Independent variable:  
Non-formal (Informal) health providers: These include traditional health providers, local 





Formal health providers: Professional health providers working in modern health facilities 
i.e. hospitals, health centers, clinics owned by government or private sector 
Drug retail outlets: includes pharmacies, drug stores, drug vendors and open market drug 
sellers 
Traditional health provides: includes traditional healers and religious healers 
Traditional healers: health providers who use mainly herbs to treat human ailments 
Local injectors: health providers with no professional training who use drugs to treat their 
clients. They mainly give injections to their clients. 
Pastoralists: People whose source of livelihood is livestock with which they move 
seasonally in search of pasture and water. 
Agro-pastoralists: People whose main source of livelihood is livestock, but also practice 
farming to some extent. 
Distance to health facility: Distance in kilo meter from patient's residence to the nearest 
health facility, at the time when patient took the decision of seeking medical care. 
No education: no formal (school) education  
Primary education: 1 to 6 years of formal education 
Post-primary education: More than 6 years of formal education 
 
2.10. Definitions of statistical terms used to assess test performance 
Prevalence: proportion of TB cases identified by culture and/or smear microscopy among all 
suspects 
Sensitivity: proportion of true positives that are correctly identified by each antigen 
Specificity: proportion of true negatives that are correctly identified by each antigen  
Likelihood Ratio of a positive test (LR+): How much more likely is a positive test to be 
found in a person with the condition than in a person without it? It is simply the ratio of 
sensitivity to 1-specificity 
Likelihood Ratio of a negative test (LR-): How much more likely is a negative test to be 
found in a person without the condition than in a person with it? It is simply the ratio of 1-
sensitivity to specificity 
 
2.11. Data collection forms 
A questionnaire was used to interview and collect data on basic socio-demographic and 





assessed using a structured questionnaire (appendix 4). The questionnaire for assessing 
diagnostic delay addressed socio-demographic characteristics, health related issues like self-
treatment, distance from the nearest health facility, knowledge on cause of TB, its seriousness 
and treatment, symptoms they are suffering from, time interval between onset of symptoms 
and first visit to a health facility, time interval between first visit of a health facility and 
diagnosis, and time interval between diagnosis and treatment.  
 
2.12. Significance of the study 
The first aim of the study was to evaluate the potential of rESAT-6/CFP-10 and rα-crystallin-
MPT-83 antigens for the diagnosis of pulmonary TB. Since this was a preliminary test 
evaluation, there was no any direct and immediate benefit from the test per se for the 
participants as well as the community they belong. However, some patients benefited from 
culture results. Moreover, as part of the global initiative to find new rapid tests for the 
diagnosis of TB, we believe that this study has added scientific knowledge in the field. 
Ultimately, identifying simple and rapid tests will have a positive impact on TB control. 
 
We have also addressed delay in the diagnosis and treatment of TB in Afar Region where 
such information is non-existent. This has generated important information on the 
contribution of patients and the health system to the total delay as well as factors associated 
with delay in the study area.  
 
2.13. Data management 
Data has been handled confidentially. Data quality was assured through pretesting of 
questionnaires, training and supervision of Interviewers, use of standard procedures for 
sample collection & storage, and use of quality control during running the laboratory tests. 
Names were replaced with a unique identity number and subsequently data was entered into 
EpiData version 3.1 & rechecked for errors, consistency, missing values and outliers. 
Subsequently it was exported into SPSS for Windows version 16 for further analysis.  
 
Simple frequency distribution with measures of central tendency (mean, median) and 
dispersion (standard deviation, range, inter-quartile range (IQR)) were run. Since data from 
serology study as well as delay study was not normally distributed, non-parametric tests 





was used for categorical variables. Multivariable logistic regression was done to identify 
independent predictors of dependent variables. In some studies, experts agreed 30 days as 
acceptable cut-off for delay [33,34] whereas the majority used median value of the observed 
data as a cut-off [35-37] and we adopted the later.  
 
Awareness regarding TB was assessed using questions addressing their knowledge about 
treatment of TB and the seriousness of the disease.  In relation to treatment, three questions 
were posed: whether TB is curable or not, fee for treatment and duration of treatment. In 
relation to seriousness of the disease, participants were asked about causes of TB, risk for 
patients and people around them before treatment. For each question, a value of 1 was given 
if correctly answered and 0 if not. Thereafter, a total score was calculated by adding the 
values for the six questions and subsequently, inter-quartile scores were calculated. 
Participants that fall into the third quartile were considered as having high knowledge and 
those below were considered as having low knowledge.   
 
The receiver operating characteristic (ROC) curve for the OD values of the antigens was 
plotted using STATA version11 and the area under the curve (AUC) and 95% CI were 
calculated. The best discrimination limit (cut-off value) for each antigen was determined 
using the ROC curve. Serum samples were identified as positive for the specific antibody 
response when the OD is greater or equal to the cut-off value. Sensitivity, specificity, and 
likelihood ratios along with their 95% CI were calculated.  In all cases, level of significance 
was set at 95 % (p <0.05) and all tests were two-tailed. 
 
2.14. Communication of Results 
Results of the study will be presented as a thesis at Department of General Practice and 
Community Medicine, Institute for health and Society, University of Oslo. Moreover, it will 
be communicated to the Afar Regional Health Bureau. Article/s will be submitted to peer-
reviewed journals for publication.  
 
2.15. Ethical consideration 
This project has been ethically cleared by the Norwegian Ethical Committee and Ethiopian 
National Ethics Committee before commencing the study. Patients who fulfilled the inclusion 





carried out in a private room by health workers. Study participants were informed on the 
purpose of the study as well as risks and benefits associated with it. Participants were granted 
their freedom to decline any time during the study and they were assured that their decision 
not to participate in the study have no impact on the routine health care they get (Appendix 
1). 
 
Local health workers speaking the local language were involved in obtaining consent to 
reduce the power structure. Interpreters were used whenever health workers speaking the 
local language were not available. Every effort was made to maintain the neutral position of 
these health workers through short training, follow up and support. After ensuring that the 
potential subject has understood the information, health workers sought the potential 
participant’s freely-given informed consent. Since the majority of the study participants were 
illiterates, the informed consent form was read and explained to them using their language 
















_____________________Chapter 3: Results__________________________ 
 
This chapter consists of 2 parts: Under 3.1, the results for the evaluation of the diagnostic 
performance of the two antigens (rESAT-6-CFP-10 and r-crystallin-MPT-83) have been 
presented.  Under part 3.2, the results of our assessment related to delay in diagnosis and 
treatment of TB is presented. Accordingly, we have two groups of study participants. The 
details of each group of participants have been described under the respective part. 
 
3.1. ELISA-based evaluation of the potential of rESAT-6-CFP-10 and r-
crystallin-MPT-83 antigens for the diagnosis of pulmonary TB 
A total of 328 participants who were identified as pulmonary TB suspects and subsequently 
sent to laboratories for smear microscopy in selected health facilities were included in this 
study. Five of the 328 participants were excluded because of the poor quality of sputum.  
Therefore, a total of 323 participants were included for further analysis. 
 
3.1.1. Socio-demographic characteristics of study participants 
The socio-demographic characteristic of study participants has been summarized in Table 
1.The mean age of study participants was 35+ 14.5 whereas the median was 30 years with the 
minimum and maximum of 18 and 80 years respectively. However, about 75 % of the study 
participants were below 45 years. The number of males was higher than females with a ratio 
of 1.4 to 1.The majority of the study participants were Muslims (73.1%) and the number of 












Table 1. Socio-demographic characteristics of pulmonary TB suspects in Northeast Ethiopia 
Variable Count   (n=323)   Percent (%) 
























































































Among the 323 patients, a total of 101 (31.3 %) were identified as pulmonary TB patients 
based on culture results. Among the 101 culture positives, 41 (40.6 %) were already 
diagnosed as smear positive pulmonary TB patients based on direct smear microscopy done 
at health facilities. Six more suspects who were reported as smear positive turned out to be 
culture negative. Therefore, the proportion of smear positive pulmonary TB patients among 
all suspects was 47 (14.6 %). Based on bacteriology result (direct smear and culture), a total 
of 107 (33.1 %) suspects were diagnosed as pulmonary TB patients. Moreover, an additional 
50 patients were diagnosed as pulmonary TB cases based on chest x-ray and clinical 
judgment even though they were both culture and smear negative. After culture result, the 
overall proportion of pulmonary TB patients among pulmonary TB suspects in the current 





However, from now on, the phrase “pulmonary TB patients” refers to those who were culture 
positive and or smear positive (bacterium positive) patients, unless specifically stated. This 
might result in some degree of misclassification of pulmonary TB patients as non-TB 
patients. 
 
3.1.2. Major symptoms reported and their association with pulmonary TB 
Participants were interviewed about the different symptoms they were suffering from. Cough 
was reported in all patients and fever was the second most frequently reported symptom 
(94.4%). Moreover, about 20% of patients reported haemoptysis.  
 
On bivariate analysis, a higher proportion of pulmonary TB patients reported fever, weight 
loss and loss of appetite compared to non-TB patients. However, none of them were 
significantly associated with pulmonary TB. Nearly 73% of pulmonary TB patients reported 
fatigue &weakness compared to 62% of non- pulmonary TB patients but the difference failed 
to reach statistical significance. Differences in the presenting symptoms among pulmonary 
















Table 2. Major symptoms reported by pulmonary TB suspects and their association with        
pulmonary TB in Northeast Ethiopia  





Cough                                   
Haemoptysis 











Fever                                       
Yes 
No                        
 
101 (94.4) 





         0.37 
 
0.55 
Loss of appetite                       
Yes 











Weight loss                              
Yes 











Night sweating                        
Yes 











Fatigue and weakness             
Yes             
 No 
 










3.1.3. Pulmonary TB and its association with socio-demographic, cultural and health-
related factors 
Bivariate analysis was done to evaluate the association between socio-demographic factors 
and other selected variables with pulmonary TB (see Table 3). Approximately 81% of 
pulmonary TB patients were below 45 years of age. The male to female ratio among 
pulmonary TB patients was approximately 2 to 1 in contrast to a 1.2 to 1 ratio in non-TB 
patients. The proportion of pulmonary TB among males (37.8%) was significantly higher 
than the proportion in females (26.7%) (2= 4.37, p=0.04).  
 
Surprisingly, the proportion of pulmonary TB patients among those who did not consume raw 
milk regularly was significantly higher (39.0%) compared to the proportion among those who 
consume raw milk regularly (27.8%) (2=4.52, p=0.03). Moreover, there was a significant 
association between educational status and prevalence of pulmonary TB (2=7.29, p=0.02); 
the proportion of pulmonary TB was lowest among suspects with no formal education and 





On multivariable logistic regression, all but raw milk consumption lost statistical 
significance. After controlling for socio-demographic variables, those who did not consume 
raw milk regularly were 1.75 times more likely to have pulmonary TB compared to those 
who consume raw milk (Adjusted Odds Ratio (ORadj.)=1.75, CI 1.06-2.91). 
 
Table 3. Association of pulmonary TB with socio-demographic, cultural and health-related 
























































































































































































3.1.4. Associations of HIV infection with socio-demographic variables 
Out of 323 participants, a total of 293 participants were tested for HIV infection and 82 
(28%) were positive. The prevalence was lower in males (26.1%) compared to the prevalence 
in females (30.5%) although this difference was not found to be statistically significant. The 
peak HIV prevalence in females occurs at younger age compared to males. With regard to 
females, the peak HIV prevalence was among those between 18 and 24 years old and nearly 
72% of HIV infection was found in those between 18 and 34 years of age. On the other hand, 
the peak HIV prevalence among males was between 35 and 44 years of age and 
approximately 77% of HIV infection occurred in those between 25 and 44 years of age. 
   
The associations of HIV infection with socio-demographic variables has been assessed using 
bivariate and multivariate analysis (logistic regression) and summarized in Table 4. On 
bivariate analysis, age, residence, occupation, literacy and ethnicity were found to be 
significantly associated with HIV infection. However, multivariable logistic regression 
indicated that Afar ethnicity was independently associated with low HIV infection 
(ORadj.=0.28, CI 0.10-0.79); whereas primary education was independently associated with 
















Table 4. Associations between HIV infection and socio-demographic variables among 
pulmonary TB suspects in Northeast Ethiopia  
Variable  HIV positive 
(n=82) 
HIV negative  
(n=211) 
 






























































































0.17  (0.07-0.43) 
 




































 Significant at p=0.05                                                        
3.1.5. HIV infection and TB 
The associations between HIV infection with pulmonary TB has been analyzed in relation to 
smear microscopy, culture and clinical diagnosis. The influence of HIV infection on the 
diagnostic potential of the two antigens has been analyzed as well (Table 5 summarizes the 
findings). 
 
The proportion of HIV infection among 101 pulmonary TB patients was 36.6% whereas the 
corresponding proportion among 192 non-TB patients was 23.3%. Pulmonary TB patients 
were 1.9 times more likely to have HIV infection compared to non-TB patients (OR=1.9, CI 





suspects was 45.1% whereas the corresponding proportion among 211 HIV negative 
pulmonary TB suspects was 30.3%.  HIV infected pulmonary TB suspects were 1.89 times 
more likely to be pulmonary TB patients than HIV negative pulmonary TB suspects 
(OR=1.89, CI 1.08-3.30).  
 
Taking all patients diagnosed as pulmonary TB based on smear microscopy, culture and 
clinical judgement, the proportion of pulmonary TB patients among 82 HIV infected suspects 
was 59.8% whereas the proportion of pulmonary TB patients among 211 HIV negatives was 
43.1%. HIV infected suspects were 1.96 times more likely to be pulmonary TB patients than 
HIV negative suspects (OR=1.96, CI 1.13-3.40). 
 
The influence of HIV infection on the results of smear microscopy has been assessed among 
95 culture positive pulmonary TB patients. It has been found that 30 (48.4%) of the 62 HIV 
negative pulmonary TB patients were smear positive compared to only 8(24.2%) of the 33 
HIV positive pulmonary TB patients. There is a 66% reduction in smear positivity among 
HIV infected pulmonary TB patients compared to HIV negative pulmonary TB patients 















Table 5.  Association of HIV infection with pulmonary TB according to the different 




































Smear microscopy result  
































‡ Diagnosis based on smear microscopy, culture, chest x-ray and clinical judgment 
Significant at p=0.05 
 
3.1.6. Accuracy of smear microscopy and physician’s diagnosis  
The overall accuracy of smear microscopy has been assessed using culture as a reference. It 
was found that smear microscopy has a low sensitivity (40.6%) with a specificity of 97.3%. 
The positive and negative predictive values were 87.2% and 78.3% respectively (table 6).  
Furthermore, the accuracy of smear microscopy in government (Table 7) and private health 
facilities (Table 8) has been assessed separately. It was found out that there is a significant 
difference (2=7.86, p=0.005) in the sensitivity of smear microscopy in the two groups of 
health facilities: 52.6% in government compared to only 25% in private health facilities. 
However, the corresponding specificities of smear microscopy were comparable: 100% in 









Table 6. Accuracy of smear microscopy for the diagnosis of pulmonary TB in Northeast 
Ethiopia 




      AFB 
 
 
Sensitivity = 40.6%                                         Specificity = 97.3% 
         LR positive=15.03                                     LR negative= 0.61 
 
Table 7. Accuracy of smear microscopy for the diagnosis of pulmonary TB at Government 
health facilities in Northeast Ethiopia 







                        Sensitivity =52.6%                                        Specificity = 96.0% 






 Positive Negative Total 
Positive 41 6 47 
Negative 60 216 276 
Total 101 222 323 
 Positive Negative Total 
Positive 30 6 37 
Negative 27 144 171 





Table 8. Accuracy of smear microscopy for the diagnosis of pulmonary TB at private health 
facilities in Northeast Ethiopia 







Sensitivity =25%                                          Specificity =100% 
               LR positive= Infinitive                                LR negative= 0.75 
 
Accuracy of physician’s diagnosis based on clinical, direct smear microscopy, and or chest x-
ray results was assessed for its accuracy against culture (Table 9). The overall sensitivity and 
specificity of physician’s diagnosis was 66.3% and 74.8%, respectively. The specificity of 
physician’s diagnosis is low compared to smear microscopy. About 72% of suspects were 
accurately diagnosed as TB or non-TB patients.   
 
We further analyzed the impact of HIV infection on physician’s diagnostic accuracy. We 
found that HIV infection influences physician’s diagnostic accuracy (Table 10 & 11). The 
sensitivity in HIV negative pulmonary TB patients was 72.6% compared to 54.5% in HIV 
positive pulmonary TB patients, although this difference failed to reach statistical 
significance (2=3.14, p=0.08). Similarly, the specificity in HIV negatives was 80.5% 
compared to 65.3% in HIV positive non-TB patients and this difference was found to be 





 Positive Negative Total 
Positive 11 0 11 
Negative 33 72 105 





Table 9.  Overall accuracy of physician’s diagnosis of pulmonary TB in Northeast Ethiopia 






          Sensitivity = 66.3%                         Specificity = 74.8% 
                  LR positive=2.63                         LR negative =0.45 
 
                               
               
Table 10. Accuracy of physician’s diagnosis of pulmonary TB among HIV negative suspects 
in Northeast Ethiopia 






   
Sensitivity =72.6%                               Specificity = 80.5% 






 Positive Negative Total 
TB 67 56 123 
Non-TB 34 166 200 
Total 101 222 323 
 Positive Negative          Total 
TB 45 29  74 
Non-TB 17 120 137 





Table 11. Accuracy of physician’s diagnosis of pulmonary TB among HIV positive suspects 
in Northeast Ethiopia 






Sensitivity =54.5%                                                       Specificity =65.3% 
         LR positive= 1.57                                                   LR negative=0.70 
 
3.1.7. Accuracy of rESAT-6-CFP-10 and r-crystallin-MPT-83 antigens  
Taking culture as a reference, 89 serum samples from 101 culture positives and 115 serum 
samples from 216 culture and smear negatives were randomly selected and ELISA was run 
on these samples. The 6 smear positive but culture negative patients were excluded from the 
ELISA test.  
 
Summary statistics has been done for the OD values of the two antigens and their mean 
values are higher than the corresponding median values in both antigens indicating skewed 












 Positive Negative Total 
TB 18 17 35 
Non-TB 15 32 47 





Table 12. Summary statistics of OD values for rESAT-6-CFP-10 and r-crystallin-MPT-83 
in culture positive and negative patients in Northeast Ethiopia 
 












35(20-60) 30(19-55) 0.11 
rESAT-6-CFP-10 Mean+ SD 0.34+0.31 0.73+0.86  
 5
th
 percentile 0.14 0.18  
 10
th
 percentile 0.15 0.21  
 25
th
 percentile 0.17 0.24  
 Median 0.23 0.35 <0.001 
 75
th
 percentile 0.35 0.88  
 90
th
 percentile 0.71 2.34  
 95
th
 percentile 0.91 3.27  
r-crystallin-MPT-83 Mean + SD 0.99+0.55 1.124+0.70  
 5
th
 percentile 0.40 0.37  
 10
th
 percentile 0.45 0.45  
 25
th
 percentile 0.55 0.64  
 Median 0.81 0.91 0.29 
 75
th
 percentile 1.28 1.30  
 90
th
 percentile 1.79 2.43  
 95
th
 percentile 2.21 2.67  
 Significant at p=0.05                         Culture and smear negatives 
 
Histogram of OD values has been constructed for both antigens and the distribution is skewed 
to the right with extreme values (see Figure 1 & 2). One sample Kolmogorov-Smirnov test 
was done as well and p-value for both is below 0.001 indicating that the distribution of OD 
values for both antigens is far from normal distribution. Log transformation was done and 





values of rESAT-6-CFP-10 remained skewed. Therefore, non-parametric method was used 
for further analysis.  
 
 













Possible association of some selected variables with OD values of pulmonary TB suspects 
has been evaluated using Mann-Whitney (for two groups) and Kruskal-Wallis (for three or 
more groups) tests. The result is summarized in Table 13. For rESAT-6-CFP-10 antigen, 
vaccination with BCG has been associated with higher median OD values compared to the 
non-vaccinated group (median of 0.44 in vaccinated versus 0.26 in non-vaccinated) and this 
difference has been found to be statistically significant (p=0.004). Similarly, the median OD 
values for r-crystallin-MPT-83 antigen among vaccinated and non-vaccinated groups has 
been found to be 1.02 and 0.82 respectively; however, this difference did not reach statistical 
significance (p=0.052).  
 
On the other hand, there was no statistically significant association of median OD values for 
the two antigens with sex, age, ethnicity, ingestion of raw milk, contact with TB patients, 
being pastoralist, smear result of culture positive pulmonary TB patients and HIV infection 





















Table 13. Associations of socio-demographic, cultural and health-related factors with OD 
values for the two antigens in Northeast Ethiopia 





































































































































































 rESAT-6-CFP-10           ‡r-Crystallin-MPT-83          Significant at p=0.05     
 
                      
For rESAT-6-CFP-10 antigen, the median OD values of smear positives (n=37) and negatives 
(n=52) among culture positive pulmonary TB patients (n=89) was compared using Mann-
Whitney test and there is no statistically significant difference between them (p=0.733). 
Similarly, there is no statistically significant difference in the median OD values of smear 
positives (n=37) and negatives (n=52) among culture positives (n=89) for r-crystallin-MPT-





For both antigens, OD values of culture positive and negative patients were compared to see 
if there is a difference. Summary statistics (table 12) and box plots (Figures 3 and 4 ) show 
that there is a difference between culture positive and culture negative patients in their 
median OD values for both antigens; however, the  difference for rESAT-6-CFP-10 antigen 
was more  striking where culture positive patients having higher OD values  compared to 
culture negative patients. Moreover, from the box plot, we can see that OD values for rESAT-
6-CFP-10 in culture positives was more skewed and spread compared to culture negatives. 
However, for r-crystallin-MPT-83 antigen, there was no much difference in skeweness and 
spread of OD values of culture positive and negative patients.  
 
Mann-Whitney test has been done to see if the difference in the OD values for culture 
positive and negative patients was statistically significant. For rESAT-6-CFP-10, the median 
OD value (0.34) of culture positives was significantly higher than the median OD value 
(0.23) of culture negatives (Mann-Whitney, p<0.001) indicating a stronger IgG specific 
immune response in culture positive pulmonary TB patients. However, for r-crystallin-
MPT-83 antigen, there was no statistically significant difference in the median values of 




Figure 3.  OD values of culture positive and culture negative patients to rESAT-6-CFP-10 









Figure 4. OD values of culture positive and culture negative patients for r-Crystallin-MPT-
83 antigen in Northeast Ethiopia 
 
 
Non-parametric ROC curve for the two antigens has been constructed as sensitivity versus 1-
specificity taking each OD value as a possible cut-off point. AUC for a ROC curve of a test is 
a summary measure of the overall performance of the test. The higher the value the better the 
test performance is. AUC for rESAT-6-CFP-10 antigen was 0.708 (CI 0.625- 0.768). This 
means a randomly picked culture positive patient had a probability of 0.708 to have a higher 
OD values for rESAT-6-CFP-10 antigen compared to a randomly picked culture negative 
patient. On the other hand, AUC for r-crystallin-MPT-83 antigen was 0.543 (CI 0.463-
0.623) indicating that this antigen had low discriminating ability. The probability of a 
randomly selected culture positive patient to have a higher OD values  compared to a 
randomly picked culture negative patient is just 0.543 which is very close to 0.5, a value that 
is expected on tossing a coin. 
 
Based on the ROC curve, the optimum sensitivity and specificity of rESAT-6-CFP-10 were 
determined to be 57.3% and 71.3% respectively. Based on these values, the cut-off value was 





low sensitivity. Alternatively, a lax threshold would result in a higher sensitivity (91.2%) but 
a lower specificity (42.2%). On the other hand, a strict threshold would result in a low 
sensitivity (20%) and a high specificity (96%). Figure 5 below shows three possibilities of 
sensitivity and 1-specificity taking three different threshold (cut-off) values. 
 
 Likewise, the optimum sensitivity and specificity of r-crystallin-MPT-83 from the ROC 
analysis were 20% and 92% respectively and the corresponding  cut-off value was found to 
be 1.85 (Figure 6).  
 
 
                                   AUC=0.708 (0.625-0.768),    Se=0.036 
 Figure 5.  ROC curve of OD values for rESAT-6-CFP-10 antigen among pulmonary TB 








AUC=0.543 (CI 0.463-0.623),   Se=0.041 
Figure 6. ROC curve for OD values of r-crystallin-MPT-83 antigens among pulmonary TB 
suspects in Northeast Ethiopia 
 
Following determination of cut-off values for the two antigens, those patients evaluated by 
the ELISA test were dichotomized as negative if their OD values are less than the cut-off 
value or positive if their OD values are greater or equal to the cut-off values (0.32 for rESAT-
6-CFP-10 and 1.85 for r-crystallin-MPT-83). Subsequently, 2 by 2 tables were constructed 
and sensitivity, specificity, predictive values and likelihood ratios were determined.  
 
The sensitivity and specificity of rESAT-6-CFP-10 were 57.3% and 71.3%, respectively. 
About 65% of the suspects were correctly classified as pulmonary TB or non-pulmonary TB 
patients. The positive and negative predictive values were 61.7% and 68%, respectively, 
whereas the positive and negative likelihood ratios were 2.00 and 0.60, respectively (Table 
14). Accuracy of the combination of smear microscopy and ELISA using rESAT-6-CFP-10 
antigen was assessed.  In a scenario in which a subject was considered to have a negative 
result when both smear microscopy and ELISA for rESAT-6-CFP-10 results were negative, 
the sensitivity was 75.3% and the specificity was 68.7%. Although both tests combined 





compared to the specificity of smear microscopy and remained similar with the specificity for 
rESAT-6-CFP-10 antigen alone. 
Subgroup analysis was done to see the accuracy of this antigen among smear negative but 
culture positive pulmonary TB as well as HIV-TB co-infected patients. The sensitivity of this 
antigen among smear negative but culture positive pulmonary TB patients (57.7%) was not 
significantly different (2=0.01, p=0.93) from the sensitivity among smear positive, culture 
positive pulmonary TB patients (56.8%). The sensitivity and specificity of this antigen among 
HIV positives were 50% and 73.9%, respectively whereas the sensitivity and specificity 
among HIV negatives were (61.4%) and (70.8%), respectively; however, there was no 
statistically significant difference in the sensitivity (2=1.09, p=0.30) and specificity 
(2=0.09, p=0.78) of the antigen among HIV positives and negatives.  
 
Table 14. Accuracy of rESAT-6-CFP-10 antigen in the diagnosis of pulmonary TB in 
Northeast Ethiopia 









Sensitivity (CI) =57.3% (46.9%- 67.1%) 
Specificity (CI) =71.3% (62.5%- 78.8%) 
LR
+ 
=2.00 (1.42-2.80)                                LR
- 
=0.60 (0.46-0.78)  
Accuracy=65.2% 
 
The sensitivity and specificity of r-Crystallin-MPT-83 were 20.2% and 92.2%, respectively. 
The positive and negative predictive values were 66.7% and 59.9%, respectively whereas the 
positive and negative likelihood ratios were 2.58 and 0.87, respectively. About 60% of the 






















patients were accurately picked as pulmonary and non-pulmonary TB patients (Table 15). 
The accuracy of this antigen combined with smear microscopy was assessed. In a scenario 
where a subject is considered negative when smear and ELISA using r-crystallin-MPT-83 
antigen results are negative, the sensitivity was 51.7% and the specificity was 87%. Although 
the sensitivity of smear microscopy has increased by nearly 11%, there is a concomitant drop 
in its specificity when combined with ELISA results of this antigen. 
 
Further subgroup analysis was done and accordingly, the sensitivity of this antigen among 
smear negative but culture positive pulmonary TB patients was 17.3% compared to the 
sensitivity among smear positives (24.3%); however, this difference was not found to be 
statistically significant (2=0.58, p=0.46). The sensitivity and specificity of this antigen 
among HIV infected and non-infected pulmonary TB suspects were not significantly different 
(p>0.05). Among HIV infected pulmonary TB patients, the sensitivity and specificity of this 
antigen were 18.8% and 95.7%, respectively whereas among non-HIV infected pulmonary 
TB patients, the sensitivity and specificity were 21.1% and 91%, respectively. 
 
Table 15. Accuracy of r-Crystallin-MPT-83 antigen in the diagnosis of pulmonary TB in 
Northeast Ethiopia 







       
Sensitivity (CI) =20.2% (13% -30%) 
Specificity (CI) = 92.2% (86% -96%) 
LR
+ 
= 2.58 (1.22-1.48)                          LR
- 
= 0.87 (0.77-0.97) 
                                    Accuracy= 60.8% 
 






















3.2. Assessment of delay among TB patients in Afar Region, Ethiopia  
3.2.1. Sample distribution  
A total of 216 patients diagnosed with different forms of TB and came to DOTS clinics of 
two government health facilities in the Afar Regional State were interviewed using a 
structured, pretested questionnaire. Socio-demographic characteristics of the study population 
are summarized in Table 16. The mean age of study participants was 32.73 +12.29 with a 
median of 30 years and range of 18 to 88 years. The vast majority (83.8%) of study 
participants were under 45 years of age. 
 
Among study participants, the number of males was found to be higher than females with a 
ratio of 1.67:1. The proportion of those with no education (64.8%) exceeded those with 
education (35.2%) and pastoralists accounted for 42.1% of study participants. Moreover, 
90.1% of pastoralists did not have education compared to just 46.4% among non-pastoralists. 
 
About 36.6% of study participants lived in a typical Afar traditional house locally named as 
“Debora” which can easily be moved from place to place. The mean distance of participants’ 
dwelling from health facilities was 14.5 km with a median of 3 km. The majority (75%) of 
study participants reported to live within 10 km radius from health facilities. However, when 
the study participants were grouped as pastoralists and non-pastoralists, the mean distance for 
pastoralists became 24.2 km with a median of 13.3 km whereas for non-pastoralists the 
respective values were 7.5 km and 2.5 km. The majority (61.5%) of pastoralist lived more 
than 10 km from the nearest health facility during their initial visit compared to only 14.4% 
among non-pastoralists. Regarding the biomedical knowledge of participants on the causes, 











Table 16. Socio-demographic characteristics of study participants in Afar Region, Ethiopia 
Variable Frequency   Percent (%) 
Age                           
 18-24 
 25-44 
  >44 
































Residence                 
 Urban 
 Rural 
      
143 




Religion                    
 Muslim 
 Christian 
       
 175 
















Occupation              
 Pastoralist 
 Non-pastoralist 
        
91 




Type of house 
Debora 
Thatched house 





















Number of people in one house 
One to three 
Four to six 










Regarding the forms of TB, 137 (63.4%) had pulmonary TB and the rest (36.6%) were 
identified as extra-pulmonary TB patients. Among pulmonary TB patients, the majority 
(61.3%) of them were smear negative with low smear positivity rate (38.7%) comparable to 
the serology study presented above. 
 
Participants were asked about the symptoms they were suffering from. Patients with 
pulmonary TB reported persistent cough (100%), fever (93.4%), weight loss (92%), loss of 





patients with extra-pulmonary TB reported fever (89.9%), swelling (mainly peripheral lymph 
nodes) (73.4%), loss of appetite (77.2%), weight loss (77.2%), night sweating (64.6%), chest 
pain (25.3%), and cough (17.7%). 
 
Differences between pastoralists and non-pastoralists in relation to socio-demographic 
characteristics, form of TB, distance to the nearest health facility and first health seeking 
action were investigated. The two groups did not differ significantly with regard to age, form 
of TB and first health seeking action. However, the proportion of males, those with no 
education, Muslims and those living more than 10 km from health facilities were significantly 
higher among pastoralists compared to their respective proportions among non-pastoralists 



























Table 17. Comparison of pastoralists with non-pastoralists with respect to some 
characteristics in Afar Region, Ethiopia 
Variable   Pastoralists 





2  p-value 
Age                         
18-24    
25-44   






































































One to three 
Four to six 























































Distance to health 







                           
 












First health seeking 





















 Includes traditional healers and drug dispensers                                           Significant at p=0.05 
 
3.2.2. Health seeking action of study participants 
Patients were asked about their first health seeking action. Among all participants, 149 (69%) 
consulted someone in their social circle before seeking help from health providers. Over two- 





private health facilities whereas 11.6% went to non-formal health providers mainly traditional 
healers and drug outlets. Figure 7 shows the different health providers visited initially. 
 
Figure 7. Type of health providers first consulted by study participants in Afar Region, 
Ethiopia 
 
First health seeking action of study participants and associated factors were further 
investigated after categorizing health providers as non-formal and formal. A total of 
191(88.4%) of study participants sought help from formal health providers first and the rest 
25 (11.6%) sought help from non-formal health providers first: 7 (3.2%) sought help from 
local injectors, 9 (4.2%) went to drug outlets and 9 (4.2%) consulted traditional healers. Data 
on group differences in relation to first health seeking action was summarized in Table 18. 
There was no significant difference with regard to participants’ first health action by age, sex 






The proportion of those with no education, pastoralists and those who live at a distance of 
more than 10 km from health facilities was higher among those who sought non-formal 
health providers’ help first compared to the proportion among those who sought formal 
health providers’ help first although these differences did not reach statistical significance. 
However, the proportion of rural dwellers (56%) and those with self-treatment with home 
remedies (36%) were significantly higher among participants who sought non-formal health  
providers’ help first compared to their respective proportions (30.9% and 11.0%) among 
those who sought formal health care providers’ help (p<0.05 for both). Those who treated 
themselves reported to use butter, milk, honey, steam inhalation, massage with plant leaves, 





























Table 18. Group differences with regard to first health seeking action of study participants in 
Afar Region, Ethiopia 




health  providers 



















































































































































3.2.3. Lengths of different delays and associated factors 
In this section, the different types of delay and their association with socio-demographic as 
well as health service related factors are presented. Figure 8 depicts the different components 
of total delay. This approach helps to identify the contribution of the different components of 







First symptom    First consultation with formal health care providers 
                                                                                                            A     B     
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  Total delay 
 
                  
                       A: Diagnosis made                         B: Treatment initiated 
 
Figure 8.  Relationship among the different types of delay 
 
3.2.3.1. Patients’ delay 
Patient delay was defined as the time between onset of TB symptoms and the first 
consultation with a professional health provider. 
 
In this study, the median patients’ delay was 20 days with IQR of 8 to 60 days. Nearly 54% 
of patients were able to report to formal health providers within 20 days and about 76% of 
participants sought help within one month. The longest patient delay, 1456 days (nearly 4 
years), was reported in one patient. Except 3 patients, the rest reported within one year. 











Figure 9. Cumulative distribution of patients’ delay in seeking help from formal health 
providers among study participants in Afar Region, Ethiopia 
 
The median delay for those patients who visited non-formal health providers initially was 
very long (60 days)  compared to only 15 days for those who were first seeking help from 
formal health providers and this difference was statistically significant (Mann Whitney, 
P<0.001). For those who initially consulted non-formal health providers, the median time 
between onset of symptoms and first consultation of non-formal health providers, however, 
was just 10 days. Similarly, patients who treated themselves initially reported a longer delay 
(52.5 days)  compared to those who didn’t treat themselves (15 days) and this difference was 
statistically significant (Mann Whitney, p<0.001).  
 
Moreover, the median delay for pastoralists was twice that of non-pastoralists (30 days versus 





p<0.001).  After dichotomizing participants’ knowledge on causes, outcomes and treatment 
of TB as low and high, the median delay for those with high knowledge was 15 days as 
opposed to a 30 days delay for those with low knowledge. However, this difference did not 
reach statistical significance (Mann Whitney, p=0.058). 
 
Group differences in patient delays’ have been further evaluated using the median as the cut-
off point for comparison. Table 19 below presents summary of the findings (both bivariate 
and multivariable logistic regression).  
 
There was no significant difference with regard to patient delay by sex, marital status and 
form of TB in bivariate analysis. On the other hand, those with pastoralist identity (Crude 
Odds Ratio (ORC) = 2.72, CI 1.56-4.74), those who treated themselves (ORC =4.65, CI 1.90-
11.38), those who live over 10 km distance from health facilities (ORC = 2.13, CI 1.13-4.00), 
and those who sought help from non-formal health providers first (ORC =7.44, CI 2.46-22.53) 
were more likely to be delayed compared to their counterparts. Similarly, those participants 
older than 44 years (ORC =2.58, CI 1.07-6.24) were more likely to be delayed compared to 
those who are below 24 years of age. On the other hand, those with post-primary education 
were less likely to be delayed compared to those with no education (ORC =0.24, CI 0.09-
0.69). 
 
However, on multivariable logistic regression, self-treatment (ORadj. = 3.99, CI 1.50-10.59), 
and first health-seeking action from non-formal health providers (ORadj. = 6.18, CI 1.84-















Table 19. Association of socio-demographic and health service factors with patients’ delay in 
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3.2.3.2. Health system’s delay 
This is the time from first contact with the health system till the commencement of treatment 
for TB. In our study, 142 (65.7%) of patients were diagnosed at government health facilities 
and the rest 34.3% were diagnosed at private health facilities. 
 
The mean system’s delay was 68.70 days with a median of 33.5 days ranging from a 
minimum of 2 days to a maximum of 712 days. Only 23.1% of patients were started on 
treatment within 15 days after the first contact with the formal health providers. Forty-four 
percent of the patients were started on treatment within 1 month whereas it took nearly 3 
months for 75% of the patients to be diagnosed and start treatment after consulting a formal 
health provider; the rest 25% were diagnosed and started on treatment after 3 months. Figure 
10 below indicates the cumulative distribution of health system’s delay in the study area. 








The median number of health facilities visited before diagnosis was 2. Out of the 216 
patients, about 23% visited only one health facility until diagnosis was made. However, 
roughly 70% of patients had to visit 2 or 3 health facilities until they were notified to have 
TB. The rest (7%) of patients visited 4 health facilities until diagnosed.  
 
The median number of visits made before diagnosis was 2. Patients had up to 6 visits before 
they were diagnosed. Only 14.8% of them received their diagnosis in the first visit. About 
70% of patients were diagnosed during the second or the third visit. Figure 11 shows the 















Total number of visits
 
Figure 11. Distribution of number of visits until diagnosis was reached among TB patients in 
Afar Region, Ethiopia 
We examined the possible association between patient-related and health system-related 





system earlier experienced a longer health system’s delay. Spearman’s correlation coefficient 
was -0.31 (p<0.001).  
 
Patients were divided into delayed and non-delayed using the median patient delay (20 days) 
as a cut-off point. Subsequently Mann-Whitney test was done to see if there is a significant 
health system’s delay for those patients who came earlier assuming that diagnosis might be 
more challenging in those who presented early compared to those who come after having a 
more advanced TB. The median health system’s delay for those who consulted the health 
system within 20 days of the onset of their illness was 49 days (IQR 25-88 days). However,  
the median health system’s delay for those who consulted the health system after 20 days 
from the onset of their illness was 29 days (IQR 5-70) and this difference was statistically 
significant (Mann-Whitney, p<0.001). 
 
Those who sought help first from non-formal health providers had a shorter median health 
system’s delay (20 days)  compared to those who sought help first from formal health 
providers (35 days); however, this difference was not statistically significant (Mann Whitney, 
p=0.12).  
 
Factors which could influence health system’s delay were examined using both bivariate 
analysis and multivariate logistic regression (median health system’s delay was taken as a 
cut-off to dichotomize the data). On bivariate analysis, socio-demographic factors do not 
seem to influence health system’s delay. However, form of TB and the type of health facility 
initially visited were found to be significantly associated with health system’s delay. Table 20 
summarizes the result. 
 
Accordingly, those with extra-pulmonary TB had a significantly higher health system’s delay 
compared to those with pulmonary TB on bivariate analysis and this difference persisted in 
multivariable logistic regression (ORadj=2.08, CI 1.08- 4.04).  
 
Moreover, the type of health facility visited initially has been found to influence health 
system’s delay. In bivariate analysis, it was found that those who visited government health 
posts/clinics, health centers and private clinics/hospitals had a significantly longer health 
system’s delay compared to those who visited government hospitals.  On multivariable 





clinics/health post (ORadj=19.70, CI 6.18-62.79), health centers (ORadj. =4.83, CI 2.23-
10.43), and private clinics/hospitals (ORadj. = 2.49, CI 1.07-5.84) were independent 
predictors of longer delay. 
 
 Table 20. Association of socio-demographic and health-related factors with health system’s 



























































































































































 Significant at p=0.05 
 
Treatment delay: As a component of health system’s delay, the time taken from diagnosis 





days with a median of 1 day (IQR 1-4 days). Approximately 60% of patients were initiated 
with treatment within 2 days following diagnosis and over 90% of TB patients were started 
on treatment within 5 days. All except one patient were started on treatment in 10 days. 
 
After grouping the health facilities where diagnosis was made into private and government 
owned, analysis has been done to see if there is a difference in treatment delay. Accordingly, 
the treatment delay was longer at private health facilities with median of 4 days. The 
corresponding median values for government health facilities was 1 days respectively and 
this difference was found statistically significant (Mann-Whitney test, p<0.001). Ninety-eight 
percent of patients diagnosed at government health facilities were started on treatment within 
5 days; however, almost 22% of patients diagnosed at private health facilities were started on 
treatment after 5 days. Figure 12 below illustrates the difference in treatment delay between 








Figure 12. Group differences (private versus government owned facilities) with regard to 
treatment delay in Afar Region, Ethiopia 
3.2.3.3. Total delay 
Total delay is the time which extends from the onset of symptoms of TB until the initiation of 
anti-TB drugs. It is simply the sum of patients’ delay and health system’s delay. In our study 
the median total delay was 70.5 days with IQR of 37 to 126.75 days. Only 5.1% of patients 
were started on treatment within one month period following onset of symptoms. Three-
fourth of patients were started on treatment within 126 days (roughly 4 months).The 
maximum delay reported was 1464 days. Figure 13 below shows the cumulative distribution 
of total delay among study participants. 
 
 
Figure 13. Cumulative distribution of total delay among study participants in Afar Region, 
Ethiopia 
 
Health system’s delay has contributed a greater proportion to the total delay. Health system’s 





longer than health system’s delay in only 65 (30.1%) patients and 2 (0.9%) patients had equal 
patient’s and health system’s delay. 
 
The association of total delay with socio-demographic and health-related factors was 
examined using bivariate analysis (Mann-Whitney for two independent groups or Kruskal-
Wallis for more than two groups) and the result has been summarized in table 21. Total delay 
was not significantly associated with age, sex, marital status and educational status of study 
participants (all having p>0.05). Although it did fail to reach statistical significance (p=0.09), 
those who lived more than 10 km distance from health facilities had a longer median total 
delay (93 days)  compared to those who lived within 10 km radius (67 days). 
 
On the other hand, first health seeking action was found to significantly influence total delay 
(Kruskal-Wallis, p<0.03). Moreover, patients with pastoralist identity had a significantly 
longer total delay compared to non-pastoralists (Mann-Whitney, P=0.01). Similarly, patients 
with extra-pulmonary TB had a significantly longer total delay compared to those who had 
been diagnosed with pulmonary TB (Mann-Whitney, p=0.002). This difference has been 
further compared using line graph (Figure 14) and from the graph we can see that for a given 
number of days, the percentage of patients initiated on treatment is higher among those with 
pulmonary TB compared to those with extra-pulmonary TB and this difference was more 
pronounced for those who started treatment after about a month and before 10 months 







Figure 14. Cumulative distribution of total delay comparing patients with pulmonary and 



















Table 21. Group differences with regard to median total delay among study participants in 
Afar Region, Ethiopia 












65 (39- 153) 
 
     























































































































    <0.03 
 Mann-Whitney test                                              Kruskal-Wallis test 
 
Multivariable logistic regression analysis was done using the median value as a cut-off to 
categorize participants as delayed and not delayed. The result (Table 22) shows that having 





delay. Moreover, first visit to government health posts/clinics (ORadj. =2.55, CI 1.01-6.03) is 
an independent predictor of longer total delay.  
 
Table 22. The association of socio-demographic and health related factors with total delay 
among TB patients in Afar Region, Ethiopia 
Variable Delay, n 
>70.5  days 
No delay, n 


























































































































Significant at p=0.05                                        
In general, in this study, patient-related delay (median of 20 days) was shorter than health 
system-related delay (median of 33.5 days) and therefore, a greater proportion of the total 
delay was related to the health system. Therefore, delay in TB diagnosis and treatment in the 





_______Chapter 4: Discussion, conclusion and recommendations_________ 
Early detection and effective treatment are key strategies to control TB. Early detection 
would be possible if a high quality diagnostic test is accessible thereby shortening health 
system’s delay. Moreover, TB patients need to be aware of their illness and seek help within 
a reasonable time. However, at this point in time, diagnostic delay remains a formidable 
challenge [38] and the currently available conventional diagnostic tools for TB leave millions 
undiagnosed and untreated. Smear microscopy has been the predominant diagnostic tool in 
high burden countries; however, it has unacceptably low sensitivity (20-80%) [41,42]. In 
countries like Ethiopia where the first contact of TB patients with the health system is mainly 
at the lowest level, diagnosis of TB is challenged as a result of lack of accurate, simple and 
point-of- care diagnostic tests. Serological tests based on antibody detection have the 
potential to meet this demand. 
 
We, therefore, evaluated the potential of two fused recombinant antigens in the diagnosis of 
pulmonary TB; moreover, we have assessed delay in the diagnosis and treatment of TB in the 
study area where such information is non-existent. First, we discussed the findings related to 
the serology study and subsequently, we discussed the results of delay study. 
 
4.1. ELISA-based evaluation of the potential of rESAT-6-CFP-10 and r-
crystallin-MPT-83 antigens for the diagnosis of pulmonary TB 
A total of 323 pulmonary TB suspects were included to assess the performance of two 
recombinant fusion antigens. 
4.1.1. Distribution of the sample 
In our study, the proportion of males exceeded that of females among pulmonary TB patients 
in a ratio of about 2 to1 which is consistent with a similar study in Ethiopia [77] as well as a 
review on sex differences in the epidemiology of TB [78]. In nearly all countries, the 
notification rate among males is higher than in females [16]. Possible explanations for the 
dominance of males among TB patients might be related to differences in health seeking 
behaviour or different level of health workers' awareness resulting in under-notification in 





 The distribution of pulmonary TB by age showed that the vast majority (81.3%) of 
pulmonary TB patients were in the productive age group (<45 years) and similar findings 
have been reported in previous studies from Ethiopia [36,37,77,80].  Moreover, it has been 
documented that notification rate peaks in young adults in low income countries as opposed 
to high income countries [16].  
 
Interestingly, in our study, raw milk consumption was found to be associated with low risk of 
having pulmonary TB. A study in Sweden evaluated the relationship between human TB and 
TB infection in cattle before the era of pasteurization and chemotherapy. The investigators 
reported that there was a positive correlation between infection in man and cattle. However, 
the correlation between TB-related morbidity and mortality in man and TB infection in cattle 
was negative [81]. Infection by M.bovis may be conferring long-term protection against 
M.tuberculosis. Since the reason for such difference is not obvious from the current study, 
further study is required. 
 
4.1.2. HIV infection among pulmonary TB suspects 
HIV remains a serious health challenge in low income countries and TB is a major 
opportunistic infection among HIV infected individuals. In Ethiopia, HIV prevalence in the 
general population was estimated to be 2.1% with high urban-rural gradient: 7.7% in urban 
areas and 0.9% in rural areas [5]. In our pulmonary TB suspects, those from urban areas had a 
higher HIV prevalence (37.4%) compared to those from rural areas (14.6%), a result 
consistent with a study from Ethiopia [82] and this is a reflection of the prevalence difference 
between urban and rural residents in the general population in the country [5].  
 
In our pulmonary TB suspects, the age group from 25 to 44 has the highest HIV prevalence. 
Moreover, the peak HIV prevalence in females occurs at younger age group compared to 
males, consistent with the results reported in two studies [77,83] from Ethiopia.  
 
Analysis of the association between socio-demographic factors and HIV infection showed 
that primary education was independently associated with a higher prevalence of HIV 
infection taking those with no education as a reference group. This is in agreement with a 
study done among army recruits in Ethiopia [84]; on the other hand, a more recent study 





protective factor for HIV infection [83]. Generally, during the early years of the HIV 
epidemic, higher education was associated with greater risk of HIV infection in Africa but 
with time higher education is becoming protective although the findings are not consistent 
[85]. 
 
In this study, surprisingly, being Afar was independently associated with low HIV 
prevalence. Although, we do not have concrete evidence to support our hypothesis, the low 
HIV prevalence in Ethnic Afars might be related to their geographical and cultural 
inaccessibility to the rest of the country.  
 
We found that HIV is significantly associated with pulmonary TB. Moreover, significantly 
higher proportion of HIV positives were diagnosed clinically with pulmonary TB compared 
to HIV negatives. These findings are consistent with a study done in Ethiopia [77]. This is not 
surprising since HIV is known to be a strong predictor of progression from infection to active 
TB [86].  
 
In our study, HIV prevalence among pulmonary TB patients was 36.6% which is comparable 
with the national HIV prevalence estimate (41%) among TB patients [5]. A study done at a 
teaching referral hospital in Addis Ababa, Ethiopia [77] reported a higher prevalence (57.1%) 
among pulmonary TB patients. On the other hand, another study from South Ethiopia 
reported a lower prevalence among pulmonary TB patients compared to ours [82]. This 
difference could be explained by the difference in study population. The vast majority of 
participants in the study done in Addis Ababa were from urban areas mainly the capital 
where HIV prevalence is high in the general population. Contrary to this, a significant 
proportion (43%) of our study participants were from rural areas; besides, patients who come 
to a tertiary hospital are likely to be those with difficult diagnosis such as HIV/AIDS 
complicated with opportunistic infections resulting in a higher HIV prevalence. On the other 
hand, participants in the study from South Ethiopia were mainly (69%) rural residents, 
possibly resulting in lower HIV prevalence.  
 
In this study, we have found a higher HIV prevalence among non-TB patients compared to 
the general population and this is consistent with the study from Ethiopia [77], indicating the 





4.1.3. Accuracy of smear microscopy and physician’s diagnosis 
Based on culture results, the prevalence of pulmonary TB among pulmonary TB suspects in 
our study was 31.3% which is very close to the prevalence (33%) reported in a study from 
Ethiopia [77]. Currently used means of diagnosis of TB in the study area were compared with 
culture as a reference to see their accuracy. 
 
Diagnosis of TB in the study area mainly depends on smear microscopy, clinical judgement 
and/or radiological findings. In this study, the role of different symptoms in the diagnosis of 
pulmonary TB has been assessed and none of the common symptoms were significantly 
associated with pulmonary TB compared to non-TB patients. Other studies have reported one 
or more of the common symptoms in pulmonary TB as predictors of the disease. For 
example, a study in Ethiopia [77] identified fever as a predictor for pulmonary TB.  
Generally, the role of symptoms in predicting pulmonary TB is limited because of their poor 
specificity to TB [87].  
 
Based on direct smear microscopy, 14.5% suspects were smear positive pulmonary TB 
patients. This is relatively lower compared to a hospital-based study done in Ethiopia [77] 
which reported a smear positivity rate of 19.8% and this might be related to the low 
sensitivity of smear microscopy in our study.  In our study, the overall sensitivity of direct 
smear microscopy at health facilities was found to be 40.6%. However, the sensitivity of 
smear microscopy at government health facilities (52.6%) was comparable to the sensitivity 
(54.2%) reported by the study done in Ethiopia [77]. In general, the sensitivity of direct smear 
microscopy reported by different studies is variable, some reporting sensitivity as high as 
80% and still others reporting as low as 20%. For example, a review paper on studies 
comparing direct and processed smear [42] reported a sensitivity ranging from 31% to 80%. 
  
Furthermore, among culture positive pulmonary TB patients, the sensitivity of smear 
microscopy was found significantly lower in HIV infected patients compared to those without 
HIV infection. This is in good agreement with the study done in Ethiopia [77] and elsewhere 
[88]. Generally, pulmonary TB patients with HIV infection tend to have decreased cavitations 






The sensitivity of smear microscopy in private health facilities was significantly lower than 
the sensitivity at government health facilities. Similarly, a report on summative evaluation of 
pilot private health sites indicated that the proportion of smear positives (21.2%) is lower 
than the national averages. Private health facilities were included in the management of TB in 
Ethiopia quite recently. Piloting was started in 2006 [89] and subsequent scale-up has been 
done in 2009. It is possible that health providers especially laboratory technicians may not be 
well trained in this short period. This might in turn have affected the competency in smear 
preparation and reading. Moreover, it was observed that patients coming from rural areas 
especially Afar Region needs their result in a single day and there is a tendency to do a single 
smear examination which obviously reduces the sensitivity of smear microscopy result. There 
is a need to closely monitor private clinics apart from training and technical support. 
Moreover, research needs to be done to explore possible factors contributing for such a 
significant difference in the sensitivity of smear microscopy between the two groups of health 
facilities so that evidence-based action could be mounted to improve the contribution of 
private clinics in the fight against TB. 
 
Before culture result was ready, based on physician’s diagnosis, about 72% of suspects were 
accurately diagnosed as TB and non-TB in our study. In HIV infected patients, both 
sensitivity and specificity of physician’s diagnosis were lower, consistent with the report 
from Ethiopia [77]. This is partly a reflection of the low sensitivity of smear microscopy as 
well as chest x-ray in HIV infected patients [77]. This could indicate that a significant 
proportion of pulmonary TB patients are misdiagnosed in situations where HIV prevalence is 
high. This could lead to significant delay with a higher risk of transmission, greater morbidity 
and mortality. In this regard, the consequences of late diagnosis in HIV co-infected TB 
patients is far more grave compared to HIV negative TB patients [90,91] warranting an early 
and accurate diagnosis of TB in these group of patients. Moreover, increased awareness of 
health workers and better diagnostic tools for HIV-related pulmonary infections other than 
TB is essential. 
 
4.1.4. Diagnostic performance of rESAT-6-CFP-10 and r-crystallin-MPT-83 antigens 
A total of 204 serum samples (89 from culture verified pulmonary TB patients and 115 
culture negative non-TB patients) were included in running ELISA using two recombinant 





ELISA result showed a significantly higher OD values for rESTA-6-CFP-10 antigen among 
pulmonary TB patients compared to non-TB patients. In line with this, a study done in 
Ethiopia [92] reported a significant difference in the IgG specific immune response to 
rESAT-6 and rCFP-10 antigens between TB contacts and TB patients.  
 
However, the difference in IgG-specific immune response between TB and non-TB patients 
for r-crystallin-MPT-83 antigen in the present study was not statistically significant. 
 
We found sensitivities of 57.3% and 20.2% for rESAT-6-CFP-10 and r-crystallin-MPT-83 
antigens, respectively.  The corresponding specificities were 71.3% and 92.2% for rESAT-6-
CFP-10 and r-crystallin-MPT-83 antigens, respectively. In a review addressing the 
performance of purified antigens for the diagnosis of pulmonary TB [55], sensitivity ranging 
from 2 to 100% and specificity ranging from 44 to 100% was reported. Similarly, another 
review [49] addressed the performance of commercial serological tests and reported a 
sensitivity ranging from 10 to 90% and a specificity ranging from 47 to 100%.  A study done 
by WHO/TDR [40] on the performance of 19 commercially available rapid diagnostic tests 
for pulmonary TB reported sensitivity as low as 0.97% and as high as 59.7%. The specificity 
of each test was relatively higher than the corresponding sensitivity reported and it ranged 
from 53 to 98.7%. This is consistent with our finding where for each antigen, the specificity 
is higher than the corresponding sensitivity. 
 
Studies specifically addressing the performance of rESAT-6 and rCFP-10 antigens (through 
measuring OD values for IgG) in the sero-diagnosis of pulmonary TB either as a separate or 
fusion antigen have reported varying results. A study done in China [59] reported the 
performance of three different antigens among which rESAT-6-CFP-10 was one. The 
sensitivity and specificity of rESAT-CFP-10 among TB patients and healthy controls were 
60.4% and 73.8%, respectively and this is in good agreement with our finding for rESAT-6-
CFP-10 antigen.  
 
Another study recently reported from China [93] evaluated 17 antigens including rESAT-6-
CFP-10. The sensitivity and specificity of rESAT-6-CFP-10 antigen were 66.7% and 81.8%, 
respectively. Similarly, a study from Poland reported a sensitivity and specificity of 64.9% 





sensitivity and specificity of rESAT-6-CFP-10 antigen in our study is lower compared to the 
reports from these two studies. In these studies, they used healthy controls to determine 
specificity which might have resulted in a higher specificity [55]. On the other hand, a study 
from South Korea [94] reported a lower sensitivity for rESAT-6 (37%) and rCFP-10 (46%). 
However, in this study, the cut-off value was determined on the ROC curve when the 
specificity is 100% for each antigen. Obviously, when we increase specificity, usually, there 
is a concomitant loss of sensitivity which is most probably the case in the Korean study.  
 
To our knowledge, there are no studies which evaluated the diagnostic potential of -
crystallin-MPT-83 as a recombinant fusion or cocktail antigen. However, some studies have 
evaluated the sero-diagnostic potential of these two antigens separately. A study from Guinea 
compared the immune response of pulmonary TB patients and healthy controls to different 
antigens in a cohort study and they found that there was no significant difference between the 
two groups with regard to their immune response to MPT 83 antigen [65] which is consistent 
with our finding for the fusion antigen. Another study from the United States assessed the 
performance of different antigens together with smear microscopy in screening active 
pulmonary TB. This study reported a sensitivity and specificity of 17% and 95%, respectively 
for the 16 kDa recombinant antigen whereas the sensitivity and specificity of rMPT 83 were 
9% and 84%, respectively [63]. Our finding of high specificity with very low sensitivity for 
the fused antigen is consistent with this report. 
 
On the other hand, two studies reported a higher sensitivity for the 16 kDa recombinant 
antigen compared to ours. The first study was from the United States which assessed the 
performance of this antigen through measuring IgG, IgA and IgM; they reported a sensitivity 
and specificity of 62% and 100%, respectively for the IgG isotope [64]. Similarly, a study 
from China has reported a sensitivity of 65.7% and specificity of 91.1% [93]. Moreover, the 
later study reported a significant difference in the immune response between healthy controls 
and pulmonary TB patients. Our finding does not support the findings of these two studies 
which reported a much higher sensitivity. Apart from differences in the antigen used, the 
composition of the study population in our study was different compared to the two studies 
and this might have contributed for the difference in the sensitivity. For example, more than 





and the controls were all healthy; this might have influenced the cut-off point and hence the 
sensitivity and specificity of the antigen.  
 
Generally, the difference in the sensitivity and specificity of the two antigens in our study 
compared to others might be explained by the difference in the type and source of the antigen 
used as well as differences in the study population composition. Moreover, it has been 
reported that the performance of an antigen varies across different populations [66,95] and 
this could be an additional possible reason for the differences observed. 
 
There are reports indicating that different antigens have higher sensitivity in smear positive 
patients compared to smear negative patients [51-54,96,97] and in HIV negatives than HIV 
positives [54]. However, we did not find any significant difference in the IgG-specific 
immune response to both antigens between smear negative and smear positive patients as 
well as HIV positive and HIV negative pulmonary TB patients. A study in Denmark [66] 
showed a higher sensitivity of three antigens (TB 9.7,TB 15.3 and TB16.3) in smear 
negatives  compared to the overall sensitivities of these antigens in pulmonary TB patients 
and one antigen (TB 9.7) had a higher sensitivity in HIV positives compared to HIV 
negatives. This difference could be due to different immune response to different antigens, 
stage of the disease (TB as well as HIV) and differences in study population.  
 
Interestingly, we found a significant difference in the IgG-specific immune response to 
rESAT-6-CFP-10 antigen between BCG vaccinated and non-vaccinated patients, those 
vaccinated having higher median OD values. This is consistent with the findings of the study 
from China [93]. The Chinese study reported a significant difference in the immune response 
to -crystallin (16 kDa) antigen between vaccinated and non-vaccinated group, vaccinated 
group having higher mean OD values.  In our study, the difference in the immune response to 
r-crystallin-MPT-83 did not reach statistical significant (p=0.052); however, the median OD 
values were higher among vaccinated group compared to non-vaccinated group. Generally, 
the RD-1 which codes ESAT-6 and CFP-10 is absent from BCG strains [98] and it is not 
clear why such differences in the IgG-specific immune response between BCG vaccinated 





4.2. Delay in the diagnosis and treatment of TB patients 
A total of 216 TB patients who were sent to DOTS clinic of two health facilities in Afar 
Region were interviewed using pretested, structured questionnaire to assess the delay in 
diagnosis and treatment of TB. 
4.2.1. Distribution of the sample  
In this study, the vast majority (83.5%) were below 45 years of age and this is consistent with 
previous reports from Ethiopia [36,37,80].  Moreover, the number of males outweighs that of 
females and these findings are consistent with the national report [6] as well as the global 
trend [16].  
 
Regarding the form of TB, the proportion of pulmonary TB and extra-pulmonary TB were 
63.4% and 36.6%, respectively and this is in good agreement with the 2006 report for the 
nation [6]. However, the proportion of extra-pulmonary TB for Afar Region in 2006 was low 
(24.7%) compared to ours as well as the national figure [6]. Among pulmonary TB patients, 
the proportion of smear positive patients in our study (38.7%) was lower than the regional 
(51%) as well as the national (46%) report [6] but close to the finding(42%)  of a study from 
Tigray Region [32]. Among pulmonary TB suspects included in our evaluation of the two 
antigens, the proportion of smear positives was 37.4% which is very close to the proportion 
for those included in the assessment of delay. The difference from regional and national 
reports might be related to the fact that we have included a smaller proportion of health 
facilities and the time was also limited as opposed to a one year period for the reports. 
However, one cannot rule out the possibility of errors in compiling and reporting data at 
regional as well as national level. There might also be a bias towards smear positive 
pulmonary TB during reporting. 
 
The proportion of females was significantly lower among pastoralists compared to non-
pastoralists. Generally, the notification rate for males is higher than females in nearly all 
countries [16]; however, a further significant drop in the notification rate for females among 
pastoralists might indicate the possibility of lower access to TB diagnostics and treatment 
services among female pastoralists.  
 
Significantly higher proportions of pastoralist were illiterates and lived at greater distance 





from rural areas where the literacy rate is low compared to urban dwellers [99]. The 
proportion of Muslims (95.6%) among pastoralists is significantly higher compared to the 
proportion among non-pastoralists (70.4%) and this is consistent with the regional census 
result [2].  
 
4.2.2. Health seeking action and patients’ delay 
In our study, a surprisingly low proportion of TB patients sought help from non-formal health 
care providers in contrary to previous reports from Ethiopia [32,36,37]. However, unlike in 
our study, two [32,36] of these studies reported a low knowledge of participants about TB. A 
recent study in Afar region on knowledge and perception of pastoralist communities about 
TB reported a high degree of awareness [100] which is consistent with our finding. Although 
we did not observe a significant difference in knowledge score between those who sought 
help from non-formal health providers and those who sought help from formal health 
providers, the high degree of awareness among our study participants about TB might be a 
possible reason for their preference to formal health care providers. Information is highly 
valued among the Afar people and they heavily depend on face-to-face communication which 
is called “Dagu”. “Dagu”, a highly valued and integral part of the Afar day-to-day life, is 
considered as a social capital and traditional heritage [101]. It might be possible that 
information related to TB might have been channelled through “Dagu” resulting in high 
awareness about the disease.  
 
The median patient delay in our study is relatively short (20 days for all forms of TB, 15 days 
for pulmonary TB and 21 days for extra-pulmonary TB). The median patient delay for all 
forms of TB in our study is shorter than those reported from Ethiopia: 60 days in Addis 
Ababa [80], 30 days in Southern Ethiopia [102], 30 days in Northern Ethiopia [32], 60 days 
in Somali Region, Ethiopia [36]. Similarly, the median patient delay in our study is shorter 
than those reported elsewhere: 21 days in Botswana [103], 28 days in South Africa [104], 28 
days in Ghana [105], 28 days in Norway [106], 31 days in Thailand [107], 56 days in Nigeria 
[108] and 120 days in Tanzania [33]. On the other hand, the median patient delay in our study 
is longer than those reported in Italy (7 days), New Zealand (7 days), Taiwan (7 days), 
Thailand (11 days), Malaysia (14 days) [38] and Uganda (7 days) [109]. One study from 
India reported identical median patient delay with that of ours [110]. Compared to the WHO-





shorter than those reported for Iran, Iraq, Somali, Syria and Yemen but longer than those 
reported for Egypt and Pakistan [35].   
 
Patient awareness and early consultation is an important step towards early case detection. In 
this study, we have found that patients have, in fact, reported to health facilities within a 
reasonable time: a patient with persistent cough is generally advised to consult formal health 
care providers in 2 to 3 weeks time and in our study, at least 50% of patients were able to 
report to health facilities within 3 weeks. In highly mobile population with a relatively low 
literacy rate and poor infrastructure, it is encouraging that half of TB patients are in fact 
coming forward and seeking help from formal health providers as early as 20 days following 
the debut of TB symptoms. The high degree of awareness about TB in the study population 
might have played a key role in the early health seeking behaviour.  
 
In the present study, we have found that first visit to a non-formal health provider was an 
independent predictor of patient delay; this is consistent with the reports of two studies from 
Ethiopia [32,37] and  another study from Thailand [107]. Similarly, a study done in Tanzania 
[33] reported that patients’ delay was significantly longer for those who first visited a 
traditional healer. In our study, those patients who consulted non-formal health providers 
initially have actually did that early enough (median of 10 days); this is a good opportunity to 
decrease patient-related delay if attention is given to non-formal health providers’ awareness 
on TB so they could refer TB suspects to formal health providers early.  
 
Similarly, we have found self-treatment as an independent predictor of patient delay which is 
consistent with a previous report from Ethiopia [37]. Those patients who treated themselves 
might consult formal health care providers only after the disease gets worsened. In a 
qualitative study in Kenya, it was reported that treatment steps for TB symptoms are 
generally sequential and the usual initial response of patients to an illness is self-treatment 
[111].   
 
4.2.3. Health system’s delay 
The median health system’s delay in our study was estimated to be 33.5 days which is long 
indicating the inadequacy of the health system to diagnose symptomatic TB patients despite a 






 In comparison to previous reports, the median health system’s delay in our study is shorter: 
63 days in Uganda [109], 35 days in Botswana [103], 35 days in Malaysia [112] and 56 days 
in Ghana [105]. Moreover, it is shorter than those reported for Iran (42 days) and Pakistan (87 
days) in the WHO multi-country study [35]. However, the median health system’s delay in 
our study is longer than those reported from Ethiopia: 6 days in Addis Ababa [80] and Somali 
region [36] and 21 days in Amhara region [37]. Similarly, a shorter health system’s delay has 
been reported in 5 WHO Eastern Mediterranean Region countries (Egypt, Iraq, Somalia, 
Yemen and Syria) [35] as well as Thailand [107], Nigeria [108], Tanzania [33], and Malaysia 
[112] as compared to ours. A study in Norway [106] that included all forms of TB reported 
health system’s median delay of 33 days which is consistent with our finding. The variation 
in health system’s delay across different studies might be mainly related to the efficiency of 
the diagnostic services available as well as health workers’ awareness and skills in the 
diagnosis of TB. 
 
In the present study, extra-pulmonary TB was found to be an independent predictor for health 
system’s delay which is consistent with previous reports from Ethiopia [36], Norway [106] 
and London [113]. This is not surprising since diagnosis of extra-pulmonary TB is not as easy 
as pulmonary TB. Literally all organs could be involved and the clinical presentation is non-
specific and hence health workers may not put extra-pulmonary TB as a differential diagnosis 
of other related illnesses. Even after a patient is suspected of extra-pulmonary TB, 
confirmation of diagnosis is extremely difficult because of lack of simple and accurate 
diagnostic tests. This creates a big dilemma whether to start a patient on anti-TB medication 
based on clinical grounds; therefore, patients might be treated with several doses of 
antibiotics before commencing on anti-TB medication and this leads to delay in diagnosis and 
treatment. Although patients with extra-pulmonary TB do not pose a threat to the community 
in terms of transmission, they could suffer long term disability, high morbidity and mortality 
as a result of late diagnosis. 
 
Those patients who first visited government health posts/clinics and health centers had a 
significantly longer delay compared to those who first visited government hospitals and this 
is consistent with previous reports from Ethiopia [37] and Botswana [103]. According to a 
review, the main problem with regard to delay seems to be related to “a vicious cycle of 





failure to access specialized TB services” [38]. Government health posts/clinics do not have 
laboratory facilities for TB; moreover, they are staffed with junior nurses and health 
assistants who are primarily trained for prevention and promotion activities as well as nursing 
care. However, they are also allowed to treat minor illnesses and therefore, it is likely that TB 
patients could easily be confused and treated as simple respiratory infections or other non-
specific medical conditions. Poor skills of health professionals together with absence of 
laboratory services could have led to a significant delay in the diagnosis and treatment of TB 
patients who presented to health posts/clinics initially.  Although health centers do have TB 
diagnostics as well as treatment services, in remote areas like Afar Region, health 
professionals with good skills are lacking and therefore, patients will be examined by less 
experienced health workers mainly nurses. It is likely that TB patients, at least initially, might 
have been treated as cases of simple respiratory infections or other minor illnesses rather than 
requesting smear microscopy leading to a significant delay with increased transmission, 
morbidity and mortality.  
 
First visit to private clinics/hospitals was found to be an independent predictor of longer 
delay compared with government hospital and this is in agreement with previous studies 
[37,107,110]. However, in comparison to government health posts and health centers, there is 
a significantly shorter delay for those patients who initially visited private clinics/hospitals.  
This study was done after a major shift has taken place in the management of TB in the 
country beginning 2006: from a purely public health sector duty to Public-Private Mix 
DOTS. In order to improve the quality of care at private health facilities, USAID Private 
Sector Program provides technical support including training [89]. Therefore, it is expected 
that awareness on TB among health workers at private health facilities has increased since 
their inclusion in the management of TB. Moreover, from our observation, patients from Afar 
Region tend to visit private clinics and hospitals in Dessie Town where better qualified 
physicians as well as better diagnostics (chest x-ray and cytology) are available. These factors 
might have contributed to the early diagnosis of TB patients at private clinics compared to 
low level government health facilities in our study. 
 
The median treatment delay in our study was 1 day. This is in good agreement with the 
reports for the 7 countries in WHO Eastern Mediterranean Region (0 for Egypt, Iraq and 
Yemen; 1 for Iran and Syria; 2 for Pakistan and Somalia) [35]. A study from Ghana reported 





finding [105]. Generally, the treatment delay for patients diagnosed at government health 
facilities is acceptable. However, the median treatment delay for those patients who were 
diagnosed at private health facilities was 4 days, much longer than the median delay for those 
diagnosed at government health facilities. This is mainly due to the fact that private health 
facilities, mainly found in Dessie, are far from patients’ homes and after being notified their 
diagnosis, patients are sent with a referral sheet to the nearest health facility. In the mean time 
it is possible that patients report to the government DOTS clinic late for various reasons. 
Apart from delay in the initiation of treatment, it is possible that patients might be lost.  
Improved diagnostic services at lower government health facilities coupled with increased 
awareness of the public on the availability of such services closer to their home could avoid 
unnecessary delay after diagnosis is made. 
 
4.2.4. Total delay 
The median total delay in our study was found to be 70.5 days and this is in good agreement 
with previous reports from Ethiopia [36,37,80] as well as Nigeria [108] and Thailand [107].  
Longer median total delay was reported in Uganda [109], Botswana [103], Tanzania [33], 
Ghana [105], and Malaysia [112] compared to ours whereas the median total delay in 
Norway was shorter than ours [106].  In the WHO Eastern Mediterranean Region multi-
country study, in 5 of the 7 countries (Egypt, Iraq, Somalia, Syria, Yemen), the median total 
delay was reported to be shorter than ours and for the rest two countries (Iran and Pakistan), it 
was longer than ours [35].    
 
In our study, we have found health system’s delay as a major contributor to the total delay, 
consistent with a previous study from Ethiopia [37]. Interestingly, we found an inverse 
relationship between patient’s and health system’s delay and this is consistent with the 
finding from Botswana [103]. Those who visited the health system earlier experienced a 
longer health system’s delay and this may indicate the difficulty in making a diagnosis in 
those presented early compared to those presented late. In line with this, two studies from 
Ethiopia [36,80], reported a long median patient delay (60 days) and a short health system’s 
delay (6 days). However, in our study, it could also be related to lack of vigilance from health 
workers side in suspecting TB in those who presented early. This is an important area that 
needs further research in order to identify factors involved in delayed diagnosis of those 






In this study, we have found extra-pulmonary TB as independent predictor of longer total 
delay and as previously pointed out, this might be related to the difficulty in suspecting and 
subsequently diagnosing TB in this group of patients. 
 
A first visit to government health post/clinic remained an independent predictor of longer 
total delay and this is possibly related to the poor skills of health workers and absence of TB 
diagnostic services.  
 
4.3. Strengths and limitations of the study 
Strengths 
The serology study: 
1. A relatively large number of bacteriologically positive pulmonary TB patients were 
included in evaluating the potential of the two antigens in the diagnosis of pulmonary TB 
 
2. We recruited all pulmonary TB suspects consecutively; moreover, we included all levels of 
health facilities (a government health center, a government hospital, a private clinic as well as 
two private hospitals for the serology study). This helped us to control selection bias. 
 
3. To avoid verification bias, we used culture as a reference test in all patients for the 
evaluation of the two antigens. Moreover, culture is recommended as a diagnostic gold 
standard [44]. 
 
 The delay study 
1. A relatively large sample size was achieved for the assessment of delay within the study 
period 
 










For the serology study 
1. Serum was collected from field sites and transported for 400- 600 km with wet ice. This 
might have a negative impact on the ELISA result. We tried to avoid exposing the samples to 
undesirable temperatures. 
 
2. There is no ideal gold standard test for immune-based tests in TB. We used culture which 
is the best gold standard currently; however, sensitivity of culture is not 100% and hence we 
might have misclassified some TB cases as non-TB cases.  
For the delay study: 
1. Selection bias: since we limited our study to TB patients who reported in two government 
health facilities, we do not have any control on those who did not report to health facilities or 
who reported to private clinics as well as other government health facilities and therefore, our 
findings may not be generalized to all TB patients in the region. However, we strongly 
believe we have generated valuable information pertinent to the two health facilities and TB 
patients who takes care from these health facilities.   
 
2. Health workers were involved in interviewing participants and it is possible that patients 
might have reported a shorter time for health system’s delay to please the interviewers.  
 
 3. We adopted a cross-sectional study design to collect information on exposure and 
outcome variables. In cross-sectional study design, it is not possible to know whether the 
exposure variables precede the outcome variables. 
 
4. Recall bias is an inevitable limitation in interview-based studies and in our study, this 
problem might have been there. We have used religious holidays to facilitate in recalling and 
hence limit the impact of recall bias.  
4.4. Conclusion 
In the present study, we have evaluated the potential of two fused recombinant antigens for 
the diagnosis of active pulmonary TB in a clinical setting. Moreover, we have assessed the 






The performance of r-Crystallin-MPT-83 antigen in the diagnosis of pulmonary TB is low. 
There is no significant difference between pulmonary TB and non-TB patients in their 
median OD values for this antigen and therefore, it does not seem to be useful in the 
diagnosis of TB in the study area. On the other hand, the performance of rESAT-6-CFP-10 is 
relatively good compared to many commercial sero-diagnostic tests for TB. Although its 
sensitivity is better than smear microscopy, the corresponding specificity is low and 
therefore, it is not accurate enough to replace or supplement smear microscopy in the 
diagnosis of active TB in the study area. However, few studies have evaluated these antigens 
in a well characterized panel of sera and therefore additional work is required before giving 
sound conclusion. 
 
Assessment of delay in diagnosis and treatment of TB in the two health facilities has revealed 
that TB patients had experienced long delay. In this regard, the contribution of the health 
system was found to be considerably high. Interestingly, a significant proportion of patients 
have reported within three weeks although they experienced a longer delay at the health 
system compared to those who sought medical attention late. In general, our findings in 
relation to patients’ delay, health system’s delay, treatment delay and total delay are 
comparable to previous reports.  
 
Upon exploring possible predictors of the different types of delay, we have found self-
treatment and a first visit to non-formal health providers as independent predictors of 
patients’ delay. On the other hand, extra-pulmonary TB has been found to be an independent 
predictor of health system’s delay as well as total delay. First visit to lower level government 
health facilities (health posts/clinics and health center) as well as private health facilities were 
found to be independent predictors of health system’s delay which might be related to lack of  
better qualified health personnel as well as accurate diagnostic services. Moreover, first visit 
to government health posts/clinics was an independent predictor of total delay. 
 
In this study, we have showed that there is long delay in the diagnosis and treatment of TB 
patients and this is especially attributable to the health system. The fact that the majority of 
patients presented themselves to health facilities early enough is an indication that patients’ 





level is inadequate. Therefore, the quest for point of care diagnostic tests should remain a 
priority to make sure that TB control programmes become successful.  
4.5. Recommendations 
1. The lowest health facilities (clinics/health posts) should be equipped with simple and rapid 
diagnostic tests to reduce health system’s delay. Health workers at the lowest health facilities 
(mainly nurses and health assistants) are at the front line where most patients seek help. 
Therefore, efforts to increase the skill and awareness of them could be intensified through 
continuing medical education on clinical presentation of patients, importance of early 
diagnosis and treatment of TB patients as well as when and where to refer patients with 
possible TB. Moreover, continuous support and supervision of these health workers should be 
in place to make sure they are contributing to the overall TB control programme.  
 
2. The sensitivity of smear microscopy was found to be significantly lower in private health 
facilities compared to government health facilities. There is a need to increase the skills of 
laboratory technicians in the diagnosis of TB especially at private health facilities in the study 
area. This could be done through skill-based training of laboratory technicians on smear 
preparation and reading. Moreover, close supervision, support and motivation of laboratory 
workers at all levels would be of paramount importance. Along with improving the skills of 
laboratory technicians, National TB and Leprosy control Programme (NTLP) should make 
sure that there are good microscopes as well as continuous supply of laboratory reagents for 
smear microscopy at TB diagnostic laboratories. 
 
3. The significant health system’s delay of patients who had their first visit to private health 
facilities in the study area needs to be addressed. The country has already launched a Public-
Private Mix DOTS programme and therefore, training aiming at increasing private health 
workers’ awareness on TB as well as skills on diagnosis is essential. Moreover, close 
supervision and continued support of private health facilities is important.  
 
4. Although TB patients in our study report relatively early, nearly half of them reported after 
3 weeks. This is also the case in other parts of the country and therefore, further awareness 
creation using a well organized information, education and communication (IEC) programme 





could be effectively used to disseminate information regarding the causes, symptoms, and 
treatment of TB as well as where and when a patient with TB symptoms should seek help. 
 
Further research implications: 
1. The performance of rESAT-6-CFP-10 antigen is relatively good compared to many 
commercial TB serodiagnostic tests; however, we measured the OD values for IgG antibody 
only and it is difficult to give sound conclusion from the present study alone. Therefore, 
additional work is needed to measure the three major antibodies (IgG, IgM, IgA) in well 
characterized panel of sera.  
2. BCG lacks the gene that encodes ESAT-6 and CFP-10. However, in the present study, 
BCG vaccinated patients had significantly higher OD values. The reason for such difference 
is not clear from the current study. Therefore, more work is required to elucidate the effect of 
BCG on humoral immune response to rESAT-6-CFP-10 antigen. 
 
3. Drinking raw milk seems to be protective against pulmonary TB. However, further study is 
required to make a sound conclusion on this association as well as to identify the 
immunological basis for such protection. 
 
4. The prevalence of HIV infection among Afar ethnic pulmonary TB suspects in our study 
was significantly low compared to other ethnic groups. However, the possible reasons for 
such difference is not clear from the current study and therefore, more comprehensive (both 
quantitative and qualitative methods) research is required to confirm our result as well as 
identify protective factors which may have an important implication to contain the spread of 
HIV infection in Afar Region. 
 
5. The accuracy of smear microscopy significantly differed between government and private 
health facilities. Moreover, we have found a significant health system’s delay of patients who 
had their first visit in private facilities compared to those who visited a government hospital. 
Further research is required to identify possible reasons for this difference and hence a 
targeted intervention could be designed. 
 
6. We have found an inverse relationship between patients’ delay and health system’s delay. 





they do not receive their diagnosis (and hence treatment) early enough resulting in late 
diagnosis and treatment. 
 
7. Since our study related to delay was limited to two health facilities, a study with more 
representative sample could be envisaged to generalize to all TB patients coming to health 
facilities in the Region; this would give evidence that could be applicable to the Region as a 
whole.  
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6.1. Appendix 1  
Informed consent  
Diagnostic delay and the potential of two fusion antigens for the diagnosis of 
Tuberculosis in Northeast Ethiopia 
 
TB is one of the major health problems in Ethiopia and the HIV/AIDS epidemic is 
aggravating the spread of TB. Early and rapid diagnosis of the disease helps to treat patients 
as well as to control the disease. However, diagnosis of the disease remains a major challenge 
because of delayed consultation as well as absence of rapid and reliable diagnostic tests. 
Currently, a number of serological tests are being evaluated; similarly, we are interested to 
evaluate the potential of one of these diagnostic tests for the diagnosis of TB. The objective 
of this study is to evaluate the performance of an antigen using blood sample in the diagnosis 
of TB as well as assess the delay in diagnosis and treatment of TB in the study area.  
You are kindly requested to participate in the study.  As a TB patient reporting to the DOTS 
clinic, if you agree, you will participant in an interview about TB for about 30 minutes. You 







 On the other hand, if you are pulmonary TB suspect and agree to participate in the study, you 
will be asked to give the following samples: sputum and about 4 ml blood. You will be 
interviewed in relation to your disease for about 15 to 30 minutes. HIV testing will be done. 
You will be provided counselling both before and after testing and you are strongly advised 
to know your status. However, your decision not to be tested and know your status is 
respected. 
 
No serious complication is expected as a result of sample collection. However, during blood 
collection, you may experience some pain and discomfort. Rarely, thrombophlebitis can 
happen. If you happen to develop any complication, you will be provided treatment in the 
health institution free of charge and the cost will be covered by the project. If you are found 
to be a case of TB according to the existing diagnostic protocol of TB in the country, you will 
be treated in the health facility free of charge which is also the standard treatment even if you 
do not participate in the research.  
 
As a pulmonary TB suspect, your participation in the study will be for about 2 days which is 
the average time taken for sputum sample collection, microscopy examination and reporting 
the result routinely. If you happen to have TB, you will start treatment for your illness. On the 
other hand, if you are not diagnosed as TB patient but found to be a case of TB after culture 
result (which will take a maximum of 2 months), you will be provided with treatment and 
therefore, you are advised to come back to your physician on your appointment. There is no 
direct benefit as a result of your participation in the study. However, your participation will 
contribute for the efforts being done to develop a new test for the diagnosis of TB. 
 
Information related to your name will be treated strictly confidential. Names and identifiers 
will be coded and deleted after data collection and therefore data will be treated anonymously 
for communication of results. Informed consent forms and questionnaires will be left behind 
in a locked cabinet in Ethiopia and will be destroyed after a year. Participation in the study is 
fully voluntary and therefore you may decline from the outset. Your choice not to participate 
in the study will have no effect at all on the care you will be provided from the health facility 





6.2. Appendix 2 
Declaration of consent  
I confirm that I have been given adequate information about the research project. I have 
understood that the information I provide will be used for research purposes and the 
information related to myself will be kept strictly confidential. I am aware that participation 
in the study is fully voluntary and I can withdraw anytime without giving any reason. 
Moreover, I am fully aware that non-participation in this project will not subject me to any 
health service denial from this health facility either now or in the times to come. I confirm 
that all the information provided to me is very clear and has been conveyed by the language 
that I fully understand. Finally, I declare that I have agreed to participate in the study. 
 
Name of participant...................................................................................................................... 
Name of the person obtaining consent......................................................................................... 
Signature of the person obtaining consent................................................................................... 
Name of the person witnessing the consent…………………………………………………… 
Date............................................................................................................................................. 
Note: This form has been translated to Amharic language which is the official language in 
the study areas 
 Name and contact address of the Principal Investigator: 
Mulugeta Belay, MPhil candidate 
Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa 
Institute for Health and Society, Department of International Health, Oslo 
Tele: 0112763091 /0911679268 
Email: mulg2002@yahoo.com 
 
6.3. Appendix 3 
Questionnaire for PTB suspects 
Title of the study: Diagnostic delay and the potential of two fusion antigens for the 
diagnosis of Tuberculosis in Northeast Ethiopia 
Participant name______________________________________ code number___________ 
Zone_____________Woreda____________Kebele_________________________________ 
Name of the health institution_________________________________________________ 





1.  Age (in years)___________________________________________________________     
2.  Sex:      1= Male              2=Female 
3.  Current marital status  1=Single        2=Married     3=Widowed  4=divorced 
4. Place of residence:  1=Urban    2=Rural      
5. The highest level of education attained:        1=none     2=primary         3= post-primary          
6. Religion:   1=Muslim          2=Christian          other________________________________ 
7. Ethnicity:                        1=Afar       2= Amhara      3= Oromo    4=other 
8. Current occupation:  1=Pastoralist           2=Agro- pastoralist             
      3.  Other (describe)____________________________________________ 
9.  If pastoralist or agro-pastoralist: Herd type   
        1=Goat      2=sheep               3= cattle                    4=camel                 5= mixed    
10.  Ingestion of raw milk:                                                          1=Yes                  2= no 
11. Contact with TB patients (patients with cough:            1=Yes                   2= no 
12. If yes to 10,                 1= Family member                     2= outside family member 
13. History of previous treatment for TB:                              1=Yes                  2= no    
14. If yes to 12,          1=Treatment completed           2= treatment interrupted   
15. History of BCG (please look for BCG scar)                        1=yes                   2=no  
B. Current illness  
1. When did you start having the present illness (Date of onset for the main complaint): 
_________________________________________________________________________ 
2. When was your first visit to a health provider (be it formal or informal)________________ 
3. The first health provider visited 
   1= informal      2= formal, private      3=formal, government     
 
4. Which of the following symptoms are you suffering from?                                   
Symptoms Yes No 
Cough without blood   
Cough with blood (haemoptysis)   
Neck, armpit or groin swelling   
 Fever   
Loss of appetite   





Shortness of breathing   
Weight loss   
Night sweating   
Fatigue and weakness   
Other (please describe)   
5. Sputum collected_________________________________________________________ 
6. Serum collected__________________________________________________________ 
7. AFB result______________________________________________________________ 
8. Culture result_____________________________________________________________ 
9. Diagnosis________________________________________________________________ 
6.4. Appendix 4: 
Questionnaire for the assessment of diagnostic delay 
Title of the study: Diagnostic delay and the potential of two fusion antigens for the 
diagnosis of Tuberculosis in Northeast Ethiopia 
Participant TB Number________________________________________________ 
Zone_____________Woreda____________Kebele__________________________________ 
Date of interview_____________________________________________________________ 
Name of the interviewer____________________Signature___________________________ 
A. General information about the patient 
1. Patient category:        1=Smear positive PTB         2= Smear negative PTB           
                                       3=Extra pulmonary TB (Type)______________________________ 
2.  Age (in years)_____________________________________________________________     
3.  Place of residence:  1=Urban    2=Rural      
4.  Sex:      1= Male              2=Female  
5. Current marital status  1=Single        2=Married     3=Widowed  4=divorced  
6. The highest level of education attained:   
     1=none     2=primary         3= post-primary          
7. Religion:   1=Muslim          2=Christian          other________________________________ 
8. Current occupation:  1=Pastoralist           2=Agro- pastoralist             
         3. Other (describe)____________________________________________ 





      1=Goat      2=sheep                 3= cattle                    4=camel                 5= mixed            
10. Distance from your home to the nearest health facility:  (either in minutes, hours or km) 
__________________________________________________________________________ 
11. Type of house used for dwelling:    1= “Debora”     2= Corrugated iron sheet roof                 
             3.  Other, please describe________________________________________________ 
12. Number of rooms in the house_______________________________________________ 
13. Number of people living in the house__________________________________________ 
B. Current illness and visit to health providers: 
1. When did you start having the present illness (Date of onset for the main complaint): 
________________________________________________________________________ 
2. Which of the following symptoms are you suffering from?                                   
Symptoms Yes No 
Cough without blood   
Cough with blood (haemoptysis)   
Neck, armpit or groin swelling   
 Fever   
Loss of appetite   
Chest pain   
Shortness of breathing   
Weight loss   
Night sweating   
Fatigue and weakness   
Other: please specify_________________________________________________________ 
 3.  Which of the above symptoms most urged you to seek for medical care? 
__________________________________________________________________________ 
4.  What did you think of the type of disease you have? ______________________________ 
5.  Did you consult a person what to do/where to go for help at the onset of the present  
     illness?     1= Yes      2= No   
6.  If yes to 6, whom did you consult? Please describe________________________________ 
7.   Did you first try to treat the illness by your own using homemade remedies?          
                           1= Yes     2= No  






9. Which of the following health providers did you visit for the current illness (please order 
them as 1 for the health provider visited first and 2 for the second and so on)? 













Duration from date of 
onset of symptoms to visit 
9.1 Clinic /health post    
9.2 Health center (Government)    
9.3 Hospital (Government)    
9.4 Lower level clinic (private)    
9.5 Mid level clinic (Private)    
9.6 High level clinic/Hospital (private)    
9.7 Local injectors    
9.8 Pharmacies, drug stores, drug vendors,  open 
market drug sellers 
   
9.9 Traditional health providers (herbalists, 
religious healers, holy water, others). 
   
 For 9.8 and 9.9 please underline the specific health provider. 
10. How many times have you visited a government medical provider for your symptoms    
       before it was confirmed to be TB? 
         1= Once   2=Twice   3=Three times    4= Four times   5=Five times   6= More than five 
11. Were the above visits with the same or different medical providers? 
          1= Same       2=Different   
12. How many times have you visited a private medical provider for your symptoms before  
       it was confirmed to be TB?    
        1= Once     2=twice       3=3 times     4= 4 times     5=5 times    6= more than 5 times 
13. Were the above visits with the same or different private medical providers? 
                                                    1= Same                  2= Different  
14. Where did it become for the first time clear that the disease is TB? 
     1= TBMU (TB management unit for government health facilities)   
     2= Private medical provider        
C. If the diagnosis of TB was made at the private medical providers 





1. What did the doctor/ the health worker at the private medical provider do when he/she 
confirmed that your illness was TB? 
      1=He/she referred me to the TBMU with slides                                                      
      2=I was referred without slides                                                                                   
      3= I was started on anti-TB drugs and referred               
      4= other, please describe_________________________________________  
2. How long did it take from the time you visited the private medical provider till you were     
      told to have TB?_____________hrs/days/weeks                                                                                                                                                                                                           
3. How long did it take from the time you were referred by the private medical provider till   
     you first reported to the TBMU?_____________days/weeks. 
4. How long did it take from the time you first reported to the TBMU till you first started     
    Anti-TB drugs? ____________days/weeks 
5. How long did it take from the time you were referred by a private medical provider till you 
first started taking the anti TB drugs?_________________________days/weeks. 
D. Diagnosis made at the TBMU (at government health facilities with DOTS clinic as well 
as AFB service)  
Note: Go to question 7 if diagnosis is made at private health providers and diagnosis is 
accepted without further investigation at your TBMU 
1. Date of first visit to the TBMU? ______________________________________________ 
2. How did you decide to visit the TBMU? ________________________________________ 
     1= Referred by HP (health post)/clinic   Date Referred_____________________ 
     2= Self-Referred     Date referred_____________________ 
     3=Referred by private    Date referred_____________________ 
     4. Others, please specify, ___________________________________________________ 
3. How long did it take since you came to the TBMU till you were first seen by the doctor/    
      health worker? ________________________ hrs/days/weeks 
4. Date the patient was first seen by the doctor /health worker   
      Checked (from the patient’s card)_____________________________________________                
5. How long did it take from the time you were first seen by the doctor/ health worker till you 
first received the sputum request for AFB/x-ray/FNA? _____________hrs/days/ weeks 
6. How long did it take from the time you gave sputum or other lab tests for examination till 
you received the results?_______________________________________________________ 
7. How long did it take from the time you were notified to have TB (received AFB 





7.1 Date Anti-TB treatments were ordered checked (from the patient card) 
___________________________________________________________________________ 
7.2. Date of registration for treatment (from district registry book) 
       checked_________________________________________________________________ 
8. How long did it take from onset of the present illness till you first started anti TB     
     chemotherapy? ____________________________ (days, weeks, month) 
E.  Knowledge about TB: 
1.  Have you heard, known   about pulmonary TB? For example, TB causes chronic  
      cough? Haemoptysis?                                    1= Yes                      2= No    
1.1. If yes to 1, where has the information come from? 
        1= Family        2= Neighbors   3= Friend     4=Health workers      
        5= Media          5= Books (reading)                              
     Other, describe____________________________________________________________ 
2. If TB is treated, can it be cured?       1=   Yes       2= No      3=I do not know    
3. What do you think are the causes of TB? 
Possible causes No yes I do not 
know 
Witchcraft    
Poverty    
Bacilli    
hard work    
Sexual overindulgence    
Malnutrition    
Unventilated home    
Living together with untreated TB patient    
HIV    
other causes    
4. Do you know any danger if a TB patient is not treated?    1= Yes              2= No    
4.1 If yes, what is it? 
 For the patient, ________________________________________________________ 
 For the people around, __________________________________________________ 





6.  How long is TB treated?                  1= 1-year         2= 6-8 months        3= I do not know    
                             3=other, please describe_______________________ 
 
